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ABSTRACT 
 
 
 
 The overarching aim of this dissertation is to use health services research methods to address 
three problems in behavioral health services. This dissertation seeks to address the knowledge gaps in 
behavioral health services through the generation of evidence intended to support evidence-based 
practices (EBP). 
Previous work has examined epidemiology of behavioral health disorders in the ED, but they 
have not attempted to examine disorders by the cause of injury. Chapter 2 examines the epidemiology of 
psychiatric disorders among adults who seek care in the emergency department (ED) by cause of injury. 
Data from a national hospital discharge survey was analyzed using logistic and multinomial regression. 
Estimates are given as average marginal effects (AME) to simplify the interpretation and application. 
Intentionally-caused injury and undetermined cause of injury are significantly associated with psychiatric 
disorders. Patients with undetermined cause of injury were more likely to be diagnosed with anxiety 
disorders, depressed mood, and psychoses relative to patients with unintentional injuries 
Since there are several treatment options for obsessive-compulsive disorder (OCD), including 
cognitive behavioral therapy (CBT), serotonin reuptake inhibitors (SRIs), and combinations of these, a 
comparison of treatment effects denominated in dollars is helpful when comparing risks and benefits. 
Chapter 3 builds on previous randomized control trials of treatments for OCD in children and adolescents 
by ranks the cost-benefits of first-line treatments. The analysis aggregates treatment effects from 
published trials in meta-analytic framework and a Monte Carlo simulation of 100,000 hypothetic children 
and adolescents to derive ranked cost-benefit. Treatments strategies starting with CBT, but not CBT and 
SRIs concurrently, were the most cost-beneficial.
vii 
 
The relationship between cost-sharing and utilization of behavioral health services has been 
studied in the aggregate, but there has been little work examining the relationship by disorder and 
treatment modality. The aim of Chapter 4 is to examine the association between cost-sharing and 
utilization of psychotherapy and adherence to pharmacotherapy among insured adults with OCD.  This 
chapter utilizes the Truven MarketScan Commercial Claims and Encounters dataset to perform zero-
inflated negative binomial regression and logistic regression analyses. Increased cost-sharing was 
significantly, negatively associated with psychotherapy intensity and dose, but not associated with SRI 
adherence. 
This dissertation examined three different research questions to address gaps in the behavioral 
health services research. The findings of these chapters have implications for patients, clinicians, insurers, 
and policymakers. The results can be used to improve aspects of cost, quality, access, and efficiency of 
behavioral health services.  
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CHAPTER ONE: 
INTRODUCTION 
  
 
 
In the United States, healthcare spending accounts for 18% of the gross domestic product, or 
about $3.3 trillion annually.1 These costs have continued to rise despite the implementation of the Patient 
Protection and Affordable Care Act (PPACA) beginning in 2010. There is evidence, however, that the 
rate of increase in healthcare inflation has declined.2 Behavioral health disorders, collectively, accounted 
for the largest proportion of healthcare costs, totaling over 7% or $241.1 billion in medical costs alone3 
and an additional $262.6 billion in lost wages4 (adjusted for 2017$). The huge monetary costs aside, 
behavioral health disorders are a significant source of impairment and mortality in the U.S. and beyond.5 
Behavioral health disorders are one of the most common classes of disorders in the United States, 
affecting 18% of adults and 13% of children in a given year.6,7 These financial and human burdens 
warrant behavioral health services research targeting cost, quality, and access.  
Over the last decade, several important policy changes have increased access to behavioral health 
services. The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) eliminated some 
managed care-imposed barriers such as treatment limits, differential cost-sharing requirements, and 
differential utilization management techniques relative to general medical care.8-10 The passage of the 
PPACA in 2010 further decreased barriers by expanding the MHPAEA protections to individual plans, 
adding behavioral health services to the list of essential benefits, allowing states to expand Medicaid 
eligibility, requiring individuals to purchase insurance, and requiring coverage for dependents until age 
26.9 These changes likely contributed to increased coverage for and utilization of behavioral health 
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services,9,11-13 but they have not universally improved access, quality, or costs of services. Even among 
the insured, access remains restricted due to the use of other utilization management techniques such as 
increased use of narrow and tiered networks.14 These policy changes have done little to improve the 
quality of such services,14-16 or even the assessment of quality.17,18 Furthermore, patients with insurance 
coverage including behavioral health services still face financial barriers to accessing care.19 Additional  
research is needed to determine how insurance benefit design affects how care is delivered to behavioral 
health patients.20 In light of these ongoing challenges, more research is needed on costs, quality, and 
access for the delivery of behavioral health services.  
 
Evidence-Based Practices 
There is an increasing focus on dissemination and implementation of evidence-based practice 
(EBP),21 which is the practice of health care services arising from the culmination of clinical expertise, 
patient preferences, and best-available research evidence.22,23 Clinical expertise is accumulated by 
practitioners through years of training and treating patients in clinical settings. Patient preferences are 
determined on a case-by-case basis taking into account factors that are important to patients such as 
effectiveness, invasiveness, side effects, costs, and prognosis.23 Empirical evidence is the foundation of 
EBP and is generated using a variety of methods from basic benchtop science to worldwide 
epidemiological and economic studies.  
Prior to the use of the term EBP beginning  in 1992,24 clinical epidemiology referred to the 
critical appraisal and application of research to the practice of medicine.25 Initially, clinical 
epidemiology/EBP researchers applied classical epidemiology principles and methods to medical 
problems through conducting epidemiological studies, systematically evaluating existing research, and 
translating studies of health care services and outcomes into practice settings.26,27 Ultimately, EBP 
employed research methods to optimize costs, quality, and access of health services.  
EBPs are disseminated primarily through peer-reviewed publications, clinical practice guidelines, 
meta-analyses, and systematic reviews.28 Despite relatively widespread dissemination of EBPs, there 
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remains significant challenges to effectively implementing EBPs in the real-world. For example, one 
study found that penetration rates of EBPs among state mental health authorities was only 1-3%.21 
Another study found substantial variation in the number of EBPs between urban and rural settings.29 Even 
individuals with private insurance do not consistently receive EBP for treatment of depression,30-32 even 
though the EBPs  improve outcomes, reduce missed work, and reduce overall costs.33,34 In response, some 
insurers have pointed to the high cost of implementing and maintaining EBPs as a reason for low 
uptake,35 which necessitates new economic analyses to address these concerns. More work is needed to 
continue development and implementation of EBPs, while investigating their uptake and impact in the 
behavioral health system. 
 
Behavioral Health Services Research Methods 
 Health services research (HSR) was formally established as a field of inquiry in the early 1960s 
with the goal of supporting the triple aim of reducing costs, improving quality, and enhancing access for 
health care services.36,37 The purpose of HSR is the generation and dissemination of reliable, valid data 
that informs the use of appropriate, effective, cost-effective, efficient, and acceptable care.38 To achieve 
this end, HSR practitioners utilize a variety of tools and techniques to answer questions a regarding how 
to best provide healthcare to populations or subpopulations. 
 Individuals with behavioral health problems are one of these subpopulations. As the top category 
of disease expenditure,39,40 behavioral health is ripe for systematic evaluation and improvement. There 
have been significant improvements in financial access to care via the MHPAEA and ACA, yet 
challenges remain in terms of costs and access to behavioral health services.12 This dissertation employs 
three different methods for assessing cost, quality, and access of behavioral health services using 
secondary data analysis. The common thread within Chapters 2 through 4 is the use of HSR methods to 
generate evidence to be used to further improve structures, processes, and outcomes within mental health 
services.  
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Chapter 2 examines the epidemiology of comorbid psychiatric disorders among adults presenting 
to the emergency department (ED) for injuries. The primary aim of Chapter 2 is to provide clinicians with 
evidence to narrow the subpopulation of injury patients that should be screened for specific classes of 
psychiatric disorders within time and resourced constrained EDs. Screening could provide additional 
opportunities to improve quality of care in the ED and access to behavioral health services for patients 
screening positive. Chapter 3 uses current EBPs for obsessive-compulsive disorder (OCD) in children and 
adolescents to perform a cost-benefit analysis. The aim of Chapter 3 is to provide clinicians, patients, 
parents, and payers an empirical comparison based on expected effectiveness and costs across options. 
Insurers and/or policymakers could utilize these results to incentivize the use of the most cost-beneficial 
treatments over less beneficial or more expensive options. Chapter 4 uses economic analyses to examine 
the relationship between cost-sharing and utilization of guideline-recommended psychotherapy and 
pharmacotherapy for treating OCD in adults. Recurring cost-sharing expenses may deter patients from 
fully realizing the recommended dose or duration of the EBPs. The aim of Chapter 4 is to quantify the 
relationship between cost-sharing, visit intensity, and medication adherence to provide evidence that cost-
sharing is a blunt instrument and may have unintentional effects of deterring high-value care. The 
remainder of the Introduction provides an overview of the studies presented in Chapters 2 through 4.  
 
Overview of Chapter 2: Epidemiology of Disorders  
Chapter 2 is an examination of the association between injuries treated in the ED and comorbid 
psychiatric disorders. This chapter highlights issues of access and quality of behavioral health services in 
the ED. Improved access to behavioral health services may be achieved through selective screening at-
risk patients for disorders and linking identified patients to necessary follow-up care. Each ED encounter 
without screening represent a missed opportunity to direct patients into necessary behavioral health 
services. Moreover, since untreated psychiatric disorders can exacerbate somatic health problems though 
disruption in prescribed care.41-44 Interventions that identify barriers to optimal care may improve overall 
quality of care patients’ quality of life, and reduce costs to hospitals and payers. 
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 Patients presenting in the ED commonly have diagnosed and undiagnosed comorbid psychiatric 
disorders. One study found that one quarter of ED patients without psychiatric complaints, met the 
diagnostic criteria for major depression.45 Others have found that over 40% of patients presenting to the 
ED for a minor injury had a comorbid psychiatric disorder.46 Furthermore, there is robust association 
between chronic psychiatric disorders and injuries, generally.47   
Each year, there are an estimated 141.4 million visits to EDs nationwide, of which 40 million are 
for an injury.48 Injuries are classified by mechanism (e.g., cut, fall, poisoning, traffic accident) and cause 
(i.e., unintentional, intentional self-harm, intentional assault, and undetermined). The largest proportion of 
injuries are unintentional, followed by undetermined, intentional assault, and intentional self-harm.48  
The relationship between the cause of injury and psychiatric disorders is not well-understood. 
There is some evidence that psychiatric disorders may moderate risk aversion behavior,49-54 thus 
increasing or decreasing probability of injuries. While the relationships are not well-understood, research 
has demonstrated that psychiatric disorders are positively correlated with injury rates and recidivism.47,55-
57 Moreover, patients presenting to the ED with injuries and comorbid psychiatric disorders have more 
complications, longer lengths of stay, and higher mortality compared to patients without comorbid 
psychiatric disorders.58 
Injuries are generally easy to observe and diagnose in the ED,59,60 while psychiatric disorders are 
substantially more difficult to observe.61,62 Previous research has shown that ED clinicians have difficulty 
diagnosing patients with anxiety,61 depression,45 and other disorders.61-63 For example, attending ED 
physicians diagnosed just 2% of patients who presented with a diagnosable psychiatric disorder.62 In light 
low identification rates, ED clinicians and patients might benefit from new tools or protocols that enhance 
their ability to diagnose latent comorbidities.  
The purpose of the study was to examine the association between cause of injury and psychiatric 
disorders among patients presenting to the ED with injuries, to provide clinicians with actionable 
guidance regarding psychiatric disorder screening. A large, national discharge dataset was utilized to 
answer this research question. The study addressed three hypotheses: 1) patients with injuries are more 
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likely to have a comorbid psychiatric disorder relative to ED patients without injuries; 2) intentional 
injuries, self-inflicted, and assault-related, are strongly, positively correlated with psychiatric disorders; 
and 3) undetermined cause of injury is positively associated with psychiatric disorders.  
 There are several significant implications for the examination of the relationship between cause 
of injury and comorbid psychiatric disorders in the ED. First, quantifying the relationship between cause 
of injury and psychiatric disorders increases our understanding of the epidemiology of psychiatric 
disorders in the ED. A robust association would indicate that additional screenings are needed to identify 
comorbid psychiatric disorders in the ED. Second, patients who are appropriately identified, can be 
referred to inpatient or community-based care. Early detection of behavioral health disorders may lead to 
earlier interventions, which can reduce the likelihood of additional impairments due to disorders and/or 
could improve treatment outcomes.58 In addition, treated psychiatric disorders may reduce ED costs and 
utilization associated with ED recidivism. Third, if the associations are found to be positive and robust, 
the results may help ED clinicians narrow the subpopulation that would benefit most from the additional 
psychiatric screening. Evidence from this study can be used to introduce efficient screening protocols that 
improve access and quality of care.  
 
Overview of Chapter 3: Cost-Benefit Analysis 
 The aim of Chapter 3 is to determine the ranked efficiency of first-line treatments for obsessive-
compulsive disorder (OCD) in children and adolescents. Chapter 3 provides evidence that supports 
decision-making when selecting the most appropriate treatment. In the face of limited time and financial 
resources, clinicians, patients, parents, and payers need to understand how treatments compare in terms of 
effectiveness, costs, time, and adverse effects.64 The comparison of costs and benefits of treatments 
directly addresses areas of costs and quality of care. Access is indirectly considered since some patients 
may not be able to participate in the most effective treatments due to geographic, temporal, or financial 
barriers. Ranking alternatives allows patients and parents to make informed treatment decisions. 
7 
 
 There are few studies of cost analyses of behavioral health treatments, especially targeting 
children and adolescents.65,66 Moreover, cost-analyses need updated as new psychotherapy interventions, 
new medications, and alternative treatments are approved and disseminated. A review of the literature 
found that 67 economic studies in child and adolescent behavioral health were published between 2005 
and 2012.66 Of these 67 studies, most were clustered around a handful of broadly-classified disorders 
including autism, anxiety and depression, attention-deficit hyper-activity disorder, and conduct disorder.66 
Further research is needed for specific disorders66 in which there are well-defined diagnoses and 
treatments. One such disorder is OCD.  
 OCD affects between 1% and 2% of children and adolescents in the United States.67 Individuals 
with OCD exhibit obsessions and/or compulsions. Obsessions are recurrent, persistent, and intrusive 
thought, impulses, or images that cause significant distress and/or anxiety.68  Compulsions are repetitive 
behaviors, or mental processes that are carried out in response to the aforementioned obsession, to reduce 
anxiety, or in accordance with a rules system.68 The symptoms vary from mild to severely impairing,69 
which can lead to reductions in quality of life.70  Most children and adolescents who do not receive the 
recommended treatments will continue to exhibit symptoms into adulthood.71,72  
 The current clinical guidelines for OCD endorse cognitive-behavioral therapy (CBT) and/or 
antidepressant medication (ADM) pharmacotherapy.73 The current evidence base suggests that CBT is 
both safe and effective for the treatment of OCD with superior effects compared to ADMs.74-76 The 
evidence also supports the use of ADMs and CBT in combination,74,76-78 especially for patients that have 
more severe symptoms.73,77,79 For some patients, ADMs are the recommended first-line treatment. For 
instance, some patients are unable to participate in CBT due to disease severity or due to concerns about 
CBT availability, time and distance barriers, and cost-barriers.73 Recent research suggests that adult 
patients with at least moderate OCD symptoms prefer differing treatment modalities based on personal 
characteristics, but favor augmenting SRI therapy with CBT over augmenting with antipsychotics.80  
 Currently, there is only one cost analysis of OCD focusing on children and adolescents, but there 
are some issues with applying the findings to the U.S. healthcare system. The sole cost-effectiveness 
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study was conducted in the United Kingdom, using assumptions surrounding their health system and 
extrapolating from adult research.81 The researchers also separately analyzed behavioral therapy (BT) and 
cognitive therapy (CT) from CBT, which does not follow accepted terminology in the U.S. and may be 
misleading.81 Therefore, Chapter 3 seeks to advance the field by conducting a cost-benefit analysis of first 
line treatments for OCD in children and adolescents.  
 The purpose of the study was to compare benefits, costs, and incremental cost-benefits for 
recommended treatments for OCD in children and adolescents. The study examined and ranked three 
initial strategies: 1) CBT monotherapy, 2) ADM monotherapy, 3) concurrent ADM+CBT and four 
augmentation strategies for treatment resistant cases: 1) more CBT after initial CBT monotherapy, 2) 
more CBT after initial ADM monotherapy, 3) more ADM after initial ADM monotherapy, and 4) adding 
ADM to CBT monotherapy. Based on the lone cost-effectiveness analysis, it was hypothesized that CBT 
monotherapy would be the most cost-beneficial strategy.  
 This study makes several contributions to the field of behavioral health services research. First, it 
is the first cost analysis of OCD treatments for children and adolescents in the U.S. This is important for 
selecting the most cost-beneficial (i.e., efficient) treatment option given the totality of the evidence and 
patient considerations. Patients must choose how to allocate their limited income and time in the face of 
several treatment options and require information from cost-analyses to identify the best option. Second, 
it aggregates existing research studies using  a meta-analytic framework to allow for comparison of 
treatment effects despite not having primary data. Third, this study also improves upon generalizability 
because it minimizes heterogeneity of study participants, protocols, and practitioners between studies 
through the meta-analytic methodology.  
 
Overview of Chapter 4: Economic Analysis of Claims Data 
 Chapter 4 presents an economic analysis of the association between patient cost-sharing and 
behavioral health services utilization and medication adherence among adults with OCD. This chapter 
follows in the same line of research as the seminal work in the Rand Health Insurance Experiment (HIE), 
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which has been replicated using observational data from health insurance claims.82-101 This chapter 
utilizes a large, national commercial health insurance claims database to examine the relationship between 
cost-sharing and utilization of psychotherapy and pharmacotherapy for adults with OCD. 
 Health insurers have long struggled with the best method(s) for limiting the use of low value care, 
or care that does little to improve health but has high associated costs.102 Moral hazard occurs when 
insured patients use more health care services than they would otherwise, because the patient only pays a 
portion or none of the true cost of care.103,104 One of the means by which insurers have sought to control 
moral hazard is through increased patient cost-sharing. Cost-sharing can include copayment, coinsurance, 
and/or deductible.  
 The demand for health care services has been shown to be responsive to varying levels of cost-
sharing. The Rand HIE was conducted from 1974-1982 across six sites in the U.S.105 The study remains 
the largest, most expensive randomized control trial of health insurance in the U.S.105 The price elasticity 
of demand across all health care services was -0.20.106 This implies that for every 10% increase in 
patients’ price, patients reduced healthcare spending by 2%. However, grouping all health services 
together is problematic because the estimates of price sensitivity for behavioral health services has been 
found to vary more than somatic health service estimates.101,107-114  
 Reported estimates of price elasticity of demand for behavioral health services have shown 
variation based on sample selection, methodology, types of services assessed, and types of providers seen. 
Some have found that demand for behavioral health services is the same as somatic health services (i.e., 
about -0.20),108,115 while the majority have reported that behavioral health services are more sensitive to 
price relative to somatic health services (i.e.,< -0.20).107,110,113,114,116,117 Interpreting these findings are 
complicated by additional variation in response to price conditional on the type of services provided 
(e.g.,, outpatient, inpatient, medications).107,110,113,116,118-123 Inpatient services are less sensitive to cost-
sharing relative to outpatient services, with most studies finding no significant change in utilization of 
inpatient service following increases in cost-sharing.124 Estimates of price elasticity of demand for 
pharmacotherapy is at least, if not more, elastic than outpatient services with estimates ranging from a 2% 
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to 6% decrease in spending for each 10% increase in cost-sharing.125 There is no significant association 
between provider type and cost-sharing, although non-psychiatrist and psychiatrists are likely 
substitutes.119-121 
 The two primary treatments for adult OCD are psychotherapy and/or serotonin-reuptake 
inhibitors (SRI).126-128 Both of these treatments are widely available in the U.S., although specialty care is 
less available in rural areas.29,129,130 The decision as to which treatment to undertake is guided primarily by 
clinical necessity and secondarily by patient preferences.131 Patients have expressed that one of their chief 
concerns regarding treatment decisions is the cost of treatment.132-134 Despite this, little work has 
examined the association between patient cost-sharing and the decisions to initiate and continue 
treatments.  
 Among the more recent research examining the association between cost-sharing and 
psychotherapy there is mixed evidence regarding cost-sharing. For example, Lu et al.108 found that 
deductibles had no effect on demand for behavioral health services, but the odds of service use for 
decreased by over 3% for every 1% increase in coinsurance rates. On the contrary, Fishman et al.135 found 
that having an unmet deductible between $100 and $500 was associated with 15% lower odds of initiating 
psychotherapy for depression, but copayment had no effect on initiation or continuation. Considering 
these mixed findings, additional confirmatory work is needed.  
 The research examining the association between cost-sharing and medication adherence has 
shown that adherence decreases as price increases. In a review of over 100 articles, Goldman, Joyce and 
Zheng125 found that spending on prescription drugs decreases by 2% to 6% for every 10% increase in 
cost-sharing, with variation by drug class and disorder. Increases in medication cost-sharing was 
associated with decreases in adherence of 10% to 27% for <$50 and  ≥$50 cost-sharing levels for 
antipsychotic medications, respectively.85 Similarly, the odds of adherence decrease by 15% for every $10 
increase in the price of antidepressant medications.82  
 Despite the numerous studies examining cost-sharing and utilization of behavioral health 
services, there remains a significant gap in the examination of cost-sharing by type of service and specific 
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behavioral health disorders. The have been limited studies of depression,82,100,136-140  schizophrenia,85,90,141-
145 and substance abuse,101,146-148 while  other disorders, despite relatively high lifetime prevalence, have 
been largely neglected, such as panic disorder (4.7%), specific phobias (12.5%), social phobia (12.1%), 
generalized anxiety disorder (5.7%), PTSD (6.8%), OCD (2.3%), bipolar disorder (4.4%), impulse control 
disorders (25%).149 This study seeks to address the gap through the investigation of cost-sharing and 
treatment utilization among adults with OCD.  
Approximately 1-2% of U.S. adults are living with OCD, 150,151 which can reduce quality of life, 
152-154 and have detrimental impacts on social and emotional well-being.155,156 As previously discussed in 
the context of children and adolescents, OCD is characterized by the presence of obsessions and/or 
compulsions that cause significant distress. The recommended first-line treatment for adults with OCD is 
also the same as in children and adolescents, which includes CBT and/or SRIs.79,157-161 In light of the 
existence of effective treatments for adults with OCD, identifying barriers to care, such as financial 
barriers (i.e., costs of care) is an important factor in ensuring that EBPs are disseminated, implemented, 
and accessible.  
 The results of Chapter 4 have several implications for insurance design regarding behavioral 
health services. First, this study provides evidence of a negative association between cost-sharing and 
psychotherapy intensity and dose among adults with OCD, which is comparable to prior research 
examining cost-sharing and behavioral health disorders. Second, this research shows that cost-sharing is a 
blunt instrument as previously described124,162 since it is associated with reductions in utilization. This 
chapter shows that increased cost-sharing is associated with lower utilization of psychotherapy (a major 
EBP recommendation) as outlined in treatment guidelines. In contrast, cost-sharing is not associated with 
adherence to SRI medications; however, caution should be used when evaluating these findings due to 
uncertainty in the model. Insurers and policymakers can use these findings, and other information, when 
determining appropriate cost-sharing mechanisms and levels for different treatment modalities by 
disorder to ensure access to high-quality treatments. The findings have implications for clinicians and 
researchers since most patients do not achieve the therapeutic dose or duration as recommended by the 
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treatment guidelines, regardless of cost-sharing. Treatment decisions should take note of this and 
clinicians should address barriers in the course of treatment. Finally, researchers will need to develop 
novel ways of delivering treatments that better fit real-world utilization patterns.  
 
Summary 
 The overarching aim of this dissertation is the contribution evidence to the scientific literature 
that can be directly incorporated into EBPs for the purposes of improving cost, quality, and access of 
behavioral health services. In each of the chapters, there is focus on ways to optimize care through at least 
two of the triple aims. One cannot optimize only one domain without some negative impact or concession 
in another domain. For example, in Chapter 2, increasing quality (via identifying comorbid disorders) for 
patients with injuries in the ED, would require increasing costs due to additional trainings and policy 
implementation, staff time needed to conduct screenings, physician time to diagnose and refer patients, 
and resources to treat patients with unstable behavioral health problems. In addition, ensuring patients 
have access to care via referrals requires establishing business relationships with outpatient behavioral 
health providers (if not done within the same system), providing additional beds, and potentially 
providing free care to indigent patients. While it is relatively simple to maximize one domain, balancing 
the other two domains requires reliable, valid data.  
 There is no one correct or best method to generate the research basis for EBPs, hence this 
dissertation uses a variety of data sources and methods, and in the process demonstrates proficiency in 
health services research methods. Chapter 2 used a nationally, representative survey of ED records and 
epidemiological methods to address the research question, what is the relationship between injury and 
psychiatric disorders among patients seen in the ED? Chapter 3, utilized data from peer-reviewed 
randomized controlled trials and probability simulations to examine and rank the cost-benefits of 
recommended treatments to address the research question, what is the most efficient/ highest quality 
treatment for OCD in children and adolescents? Chapter 4 exploited a large insurance claims database and 
regression analyses to examine the relationship between cost-sharing and behavioral health service use for 
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adults with OCD. In doing so, it addressed the research question, how do financial barriers affect access 
to and quality of health care services?  
While the methodology is important, the application of findings to practice and policy are equally 
important. Each chapter provides evidence that can be incorporated in the EBPs and/or used to support 
the dissemination, implementation, and access to EBPs for patients with behavioral health disorders. The 
audience for these chapters range from patients, to clinicians, to payer and policymakers. These 
stakeholders all require reliable, valid information to make informed decisions, and in the case of the 
clinicians, implement EBPs. In our healthcare system with increasingly limited resources, it is necessary 
to identify the EBPs to maximize the return on time and monetary investments in health.  
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CHAPTER TWO: 
PREVALENCE OF PSYCHIATRIC DISORDERS VARIES BY CAUSE OF INJURY AMONG 
ADULTS PRESENTING TO THE EMERGENCY DEPARTMENT 
 
 
Introduction 
Each year, 40.2 million Americans are admitted to emergency departments (EDs) for injuries.1 
Injuries are classified on two axes: the mechanism (e.g., fall, cut, firearm, poisoning, traffic accident) and 
cause (i.e., unintentional/accidental, intentional self-harm, intentional assault-related, and undetermined). 
Unintentional injuries accounted for three-quarters of all injuries presenting to the ED in 2011.2 The 
remaining 25% of injuries include self-harm (836,000 ED visits), homicide or assaults (2.1 million), and 
those deemed to be undetermined (6.2 million).2  
Physical injuries are relatively easy for ED clinicians to observe,3,4 but clinicians often face 
challenges identifying less observable comorbidities in the ED, such as psychiatric disorders.5,6 Attending 
ED physicians diagnosed just 2% of patients meeting criteria for an undiagnosed psychiatric disorder 
based on the Mini-International Neuropsychiatric Interview (MINI).5 Similarly, in a comparison between 
prospective screenings for psychiatric disorders and ED physician diagnoses in the normal course of care, 
ED physicians had significantly lower rates of identification.7 For example, physicians only diagnosed 
2% of the sample with an anxiety disorder, yet 53% of the sample was determined to have an anxiety 
disorder.7 With regard to depression, physicians diagnosed just 6% of the sample, of which 37% met 
diagnostic criteria.7 Given low identification rates, tools to help ED clinicians identify patients with 
psychiatric disorders, and appropriate interventions could improve quality of care,8 reduce ED 
recidivism,9 and reduce morbidity and mortality10-12 associated with psychiatric disorders.  
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 Nearly a quarter of ED patients presenting for non-psychiatric (i.e., primarily somatic) 
complaints meet criteria for major depression,13 and over 40% of patients presenting for a minor injury 
have a concurrent psychiatric disorder.14 Further evidence suggests the presence of significant, positive 
associations between injuries and moderate to severe psychological distress.15 Injuries are positively 
associated with chronic psychiatric disorders causing significant impairment.16 This association is robust 
and consistent across cultures; and  has been examined in studies from South Africa,17 Canada,18 
Australia,19 Sweden,20 Denmark,21 the Netherlands,22 and New Zealand.23,24  
There is some evidence for a relationship between psychiatric disorders and the cause of injuries. 
Individuals with a psychiatric disorder have twice the number of past injuries, and 4.5 greater odds of 
injury recidivism compared to those without psychiatric disorders.9 Trauma patients with unintentional 
and intentional injuries (i.e., self-harm and assault) have a higher proportion of antisocial personality 
disorders (using DSM-III-R criteria) and depression compared to controls that have elective surgery.25 
Another study found that unintentional injuries are positively associated with depression.26 Furthermore, 
Patients presenting to the emergency department with injuries and comorbid psychiatric disorders have 
significantly more complications, longer length of stay, and higher mortality than patients without 
psychiatric disorders.27 Therefore, injury patients in the ED could benefit from new methods or tools for 
clinicians used to identify these less-visible, comorbid psychiatric disorders.  
Understanding the relationship between diagnosed psychiatric disorders and cause of injury 
related to ED visits has significant clinical implications. First, assessing the association between 
psychiatric disorders and injury visits provides evidence regarding the likelihood that ED clinicians may 
be underdiagnosing psychiatric disorders. If the association is robust, clinicians may be well advised to 
conduct screenings for psychiatric disorders during injuries in the ED. The patient can be linked with 
psychiatric services in the inpatient and outpatient settings, but only if a disorder is identified. Second, 
diagnosing psychiatric disorders in the ED may reduce injury recidivism, improve treatment outcomes, 
reduce costs and utilization of EDs.9  Earlier diagnosis of psychiatric illness may improve the likelihood 
of patients receiving effective treatments, thus reducing encounters in the ED, fewer unmanaged 
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comorbid disorders, and higher quality of life. Third, it provides empirical evidence to narrow the 
subgroup and the disorders for which to screen in the ED. For example, based on the cause of injury, the 
provider can write orders to screen the patient for the most likely psychiatric disorder(s), rather than 
ordering that an omnibus psychiatric test battery, or more likely, none at all.  
The purpose of this study is to examine the association between diagnosed psychiatric disorders 
and cause of injury for ED encounters, including self-harm, assault, unintentional, and undetermined 
injuries, in a large, U.S.-based dataset to provide guidance to ED clinicians, where the observability and 
diagnosis of psychiatric disorder is often challenging. It is hypothesized that patients with any injury are 
more likely to have a diagnosed psychiatric disorder relative to patients without injuries, consistent with 
Poole et al.25 and Wan et al.9 More specifically, it is hypothesized that self-harm and assault injuries are 
more strongly correlated with a diagnosed psychiatric disorder than unintentional injuries, following work 
by van der Westhuizen et al.17 It is further posited that there is a positive association between 
undetermined injuries and diagnosed psychiatric disorders. This study is one of the first to examine 
diagnosed psychiatric disorders by cause of injury in a national sample of EDs to provide a baseline for 
clinician-identified prevalence. 
 
Methods 
Data  
This study utilized pooled data from the 2007-2011 National Hospital Ambulatory Medical Care 
Survey (NHAMCS).28 The National Center for Health Statistics (NCHS) conducts the NHAMCS 
annually using a probability sample of ambulatory care encounters to acute care hospitals.28 The survey 
methodology has been described in detail elsewhere.28 The NHAMCS sample is population-weighted to 
reflect all ED encounters to non-institutional general and short-stay hospitals in the U.S. (excluding 
federal, Veterans Affairs, and military hospitals). The average unweighted ED response rate across study 
years was 90% (88.9% weighted).28 The unit of analysis for this study was the ED encounter. The total 
sample size, before restriction for age and missing data, was n= 135,096 encounters (525,973,326 
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weighted). After restricting for age  ≥18 and non-missing data, the final sample size was n= 132,020 
encounters, reflecting 493,402,896 encounters after weighting. This study was exempt from review by the 
University of South Florida institutional review board because it used only publicly-available, de-
identified data.  
 Psychiatric Disorder Diagnoses 
 The primary outcome of interest was the presence of a documented psychiatric disorder 
diagnosis. Diagnostic categories were determined from each of the three reported ICD-9-CM codes. An 
individual was considered to have a psychiatric disorder if they had an ICD-9-CM code for at least one of 
the following disorders: anxiety-related (300-300.9), depressed mood (296.2-296.36, 296.5-296.56, 311), 
manic mood (296-296.26, 296.4-296.46), psychoses (295-295.95, 297-297.9), and/or ‘other disorders’, 
which includes Autism spectrum disorder (299-299.91), attention deficit hyperactivity disorder (ADHD; 
314-314.9), and personality disorder (301-301.9). Two types of dependent variables were used: 1) an 
indicator for presence of any psychiatric disorder diagnosis listed above, and 2) an indicator variable for 
each psychiatric disorder. Any psychiatric disorder is used to assess the findings in the context of the 
research literature describing general psychological distress. The specific categories of psychiatric 
disorders were used to determine whether the association between any diagnosed psychiatric disorder and 
injury is moderated by the specific category of disorder. 
Cause of Injury 
Cause of injury is determined by survey-reported cause and through International Classification 
of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) external cause of injury codes (E-codes)29 
when survey reported cause is absent. Four causes of injury were available, these included unintentional 
(E800-E869, E880-E929), assault (E960-E969), self-harm (E950-E959), and undetermined (E980-E989, 
or “injury visit: no code reported”). Injuries due to medical care, operations of war, or terrorism were 
excluded from the data (E870-E879, E930-E949, and E990-E979, respectively). 
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Covariates  
Sociodemographic variables included age, sex, imputed race and ethnicity, primary payer, and 
metropolitan statistical area (e.g., measure of urbanicity). Children and adolescents (<18 years) were 
excluded from this analysis, consistent with previous studies focused on either children and 
adolescents30,31 or adults,9,15,32 but not both. Children and adolescents were conceptually different than 
adults in terms of causes of injury and psychiatric disorders (e.g., type and prevalence of disorders). Age 
is centered on the mean within the range 18-100 years. Combined race and ethnicity categories (i.e., 
Caucasian, African American, Hispanic, and other race/multiple races) were mutually exclusive, and 
where necessary, were imputed by NCHS. There were 26,289 encounters have an imputed race/ethnicity 
variable. Statistical models were analyzed with and without imputed race/ethnicity to check for potential 
bias resulting from the imputed values. The effect estimates change by less than 0.1 units and the 
confidence interval for imputed race/ethnicity estimates were completely contained within the unimputed 
race/ethnicity estimates confidence intervals; therefore, the imputed race/ethnicity is used in all analyses. 
Primary payer is coded as private insurance, Medicare/Medicaid, self-pay/uninsured, and other. 
Additional covariates include, urban/rural designation, an indicator variable for a weekend encounter 
(Saturday-Sunday vs. Monday-Friday) and year of encounter to adjust for any potential time effects.  
Statistical Analyses 
 Frequencies, proportions, and chi-square analyses were computed for dependent variables and 
independent variables. A multivariate logistic regression model is used to assess the association between 
the dependent variable, any diagnosed psychiatric disorder, and cause of injury relative to non-injury, 
controlling for covariates. A second multivariable logistic regression model is used to examine the 
association between the dependent variable, any diagnosed psychiatric disorder, and undetermined, 
assault, and self-harm injuries relative to unintentional injuries. Separate logistic models for each 
diagnosed psychiatric disorder as the dependent variable, assess the association with cause of injury 
controlling for comorbid psychiatric disorders and other covariates. The resulting regression models were 
used to calculate post-estimates of the differences in the probability of a co-morbid psychiatric disorder 
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based on the cause of injury. Post-estimation of probabilities and relative risks were calculated to improve 
the interpretation of results, since odds ratios (ORs) can be difficult to interpret, conceptualize, and may 
overestimate the true risk.33,34 Relative risk (RR) is estimated from the regression models as described by 
Knol et al.34 All analyses were conducted in Stata MP 14.2 (College Station, TX).28 
 
Results 
There were 42,285 encounters due to injuries, accounting for one-third of all documented ED 
encounters. The count and weighted percentage of each type of disorder by cause of injury as a proportion 
of all encounters is found in Table 2.1 below. Depressed mood is the most common disorder among all 
causes of injury except assault, for which psychoses is most common. The least common diagnosis across 
all causes of injury is the catch-all group ‘other diagnoses.’ 
 
Table 2.1. Sample count and weighted proportion of encounters having each psychiatric disorder by 
cause of injury for all ED encounters. n= unweighted, %= weighted, weighted total= 493,402,896 
 Anxiety 
 
Depressed 
Mood 
Manic 
Mood 
Psychoses Other Any 
Disorder 
  n (%) n (%) n (%) n (%) n (%) n (%) 
Cause of Injury       
No Injury 1,797 (1.9) 1,305 (1.1) 685 (0.4) 1,353 (0.8) 162 (0.1) 4,788 (4.0) 
Unintentional 167 (0.5) 289 (0.7) 203 (0.3) 240 (0.4) 45 (0) 859 (1.9) 
Undetermined 79 (0.7) 148 (1.0) 67 (0.3) 118 (0.7) 23 (0) 389 (2.6) 
Assault 19 (0.7) 18 (1.0) 19 (0.7) 24 (0.5) 5 (0.2) 77 (2.9) 
Self-harm 57 (0.7) 211 (28.4) 48 (3.0) 38 (3.2) 17 (1.1) 319 (39.1) 
Notes: Psychoses includes: schizophrenia and delusional disorders. 
           ‘Other’ includes: ADHD, Autism spectrum disorder, and personality disorders. 
           Neither columns nor rows will add to 100% due to omission of encounters without disorders. 
 
 
Descriptive statistics for encounters with and without a diagnosed psychiatric disorder are found 
in Table 2.2 below. The most common causes of injury were unintentional (72%), followed by 
undetermined (21%), assault (5%) and self-harm (2%). Only 3.9% (1,644) of injury encounters document 
a diagnosed psychiatric disorder at the time of encounter, compared to 5.3% (4,788) of non-injury 
encounters. Of note, there was a greater proportion of encounters with comorbid substance abuse and 
diagnosed psychiatric disorders (p <0.001). Among encounters with a diagnosed psychiatric disorder, 
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there was a larger proportion of encounters with Medicare or Medicaid (p <0.001) and a lower proportion 
of private insurance (p <0.001) compared to encounters without a diagnosed psychiatric disorder. There 
was a lower proportion of encounters with documented psychiatric disorders occurring during the 
weekend (p <0.001). There was not a significant difference in the proportion of diagnosed psychiatric 
disorders by sex (p =0.514), race/ethnicity (p =0.066), or urban/rural location (p =0.398).  
The model examining the association between having any diagnosed psychiatric disorder and 
cause of injury could not be directly interpreted due effect measure moderation by psychiatric diagnosis. 
The strong positive association between causes of injury and specific psychiatric diagnoses obscured the 
lack of association between the other psychiatric disorders when examined using a single outcome 
variable. Therefore, only the results from the disorder-specific multivariate logistic models are 
interpretable. The results of these disorder-specific models are presented in Table 2.3. Among encounters 
related to self-harm injuries, all disorders studied (i.e., anxiety, depressed mood, manic mood, psychoses, 
and other disorders) were significantly more likely to be diagnosed relative to encounters for 
unintentional injuries. For example, the odds a diagnosed anxiety disorder concurrent with a self-harm 
encounter were 7.22 (95%CI: 4.16 – 12.52) times greater relative to unintentional injury encounters. 
Relative to unintentional injuries, self-harm encounters were associated with greater odds of diagnosed 
depressed mood (OR: 42.46, 95%CI: 30.04 – 60.01), diagnosed manic mood (OR: 5.06, 95%CI: 2.87 – 
8.90), diagnosed psychoses (OR: 5.02, 95%CI: 2.25 – 11.21), and other diagnosed disorders (OR: 4.75, 
95%CI: 1.15 – 19.65). However, these results should be interpreted with caution, given the relatively 
wide confidence intervals.  
The findings suggest that the association between cause of injury and psychiatric disorders varies 
by the type of class of disorder under study. Undetermined injury encounters were positively associated 
with diagnosed anxiety disorders (OR: 1.81, 95%CI: 1.22 – 2.70), diagnosed depressed mood (OR: 1.79, 
95%CI: 1.32 – 2.43), and diagnosed psychoses (OR: 2.31, 95%CI: 1.59 – 3.35), but not manic mood nor 
other diagnosed psychiatric disorders relative to unintentional injury encounters.   
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Table 2.2. Sample counts and weighted proportion having a psychiatric disorder, or not by demographic, 
patient, and hospital-related for all ED patients. (n= unweighted, %= weighted; weighted total= 
493,402,896) 
 Full Sample 
(n=132,020) 
Psychiatric 
disorder 
Present 
(n=6,432) 
No 
Psychiatric 
disorder  
(n=125,588) 
  
 Mean ± SE Mean ± SE Mean ± SE 
Age 45.75 ± .18 41.97 ± .39 45.89 ± .18   
      
 n (%) n (%) n (%) Weighted F P 
Cause of Injury    124.00 <0.001 
No Injury 89,735(68.0) 4,788 (75.7) 84,947 (68.4)   
Any Injury 42,285 (32.0) 1,644 (24.3) 40,641 (31.6)   
Unintentional 30,268 (22.9) 859 (12.1) 29,409 (22.9)   
Undetermined 9,072 (6.9) 389 (5.1) 8,683 (6.8)   
Assault 2,155(1.6) 77 (1.4) 2,078 (1.6)   
Self-harm 790 (0.6) 319 (0.6) 471 (0.4)   
Substance Use    308.69 <0.001 
Yes 3,947 (3.16) 804 (11.1) 3,143 (2.9)   
No 102,005 (96.8) 4,483 (88.9) 97,522 (97.1)   
Sex    0.43 0.514 
Female 74,438 (57.0) 2,830 (57.7) 57,076 (57.0)   
Male 57,582 (43.0) 2,457 (42.3) 43,589 (43.0)   
Race & Ethnicity    2.46 0.066 
Caucasian   81,366 (63.7) 3,011 (66.1) 62,264 (63.7)   
African American  29,094 (21.7) 1,191(19.7) 21,686 (21.8)   
Hispanic Only 16,446 (11.6) 884 (11.4) 12,924 (11.7)   
Other or Multiple  5,114 (2.9) 201 (2.9) 3,791 (2.9)   
Insurance    51.42 <0.001 
Private  40,363 (39.2) 1,244 (29.3) 39,119 (39.6)   
Medicare/Medicaid 37,159 (33.3) 2,636 (41.9) 34,523 (32.2)   
Self-Pay 19,013 (19.0) 888 (19.3) 18,125 (18.3)   
Other/Unknown 9,417 (8.5) 519 (9.5) 8,898 (10.0)   
MSA    2.75 0.398 
Yes 90,897 (83.4) 4,767 (84.2) 86,130 (83.3)   
No 15,055 (16.7) 520 (15.8) 14,535 (16.7)   
Weekend    10.96 0.001 
Yes 29,439 (28.1) 1,263 (25.0) 28,176 (28.2)   
No 76,513 (71.9) 4,024 (75.0) 72,489 (71.8)   
Notes: SE: standard error.  
Weighted F-test assessed the between groups differences.  
MSA: metropolitan statistical area. 
 
There was no difference in the odds of diagnosed psychiatric disorders among assault-related 
encounters relative to unintentional injury encounters. Relative to encounters without substance abuse, 
encounters with substance abuse were more likely to be diagnosed with every psychiatric disorder.  
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Within each disorder-specific model, comorbid psychiatric disorders were not consistently, 
significantly (p <0.05) associated with the outcome psychiatric disorders. Among encounters with a 
diagnosed anxiety disorder, only ‘other’ psychiatric disorders were significantly more likely to be present 
(OR: 4.85, 95%CI: 1.08 – 21.73). Similarly, encounters with other diagnosed psychiatric disorders were 
7.46 (95%CI: 1.89 – 29.39) times more likely to be diagnosed with comorbid depressed mood, relative to 
encounters without ‘other’ psychiatric disorders. A diagnosis of manic mood is associated with increased 
odds of comorbid anxiety disorders (OR: 2.88, 95%CI: 1.09 – 7.59), psychoses (OR: 10.45, 95%CI: 4.79 
– 22.80), and ‘other’ disorders (OR: 11.11, 95%CI: 3.19 – 38.8).  
Having a diagnosis of psychoses was associated with increased odds of comorbid manic mood 
(OR: 10.99, 95%CI: 4.95 – 24.41). Diagnoses of other psychiatric disorders was also associated with 
increased odds of a comorbid anxiety disorder (OR: 6.00, 95%CI: 1.33 – 26.94), depressed mood (OR: 
6.37, 95%CI: 1.35 – 30.07), and manic mood (OR: 11.33, 95%CI: 2.98 – 43.12). Caution should be 
exercised when evaluating these findings considering the wide confidence intervals, which were due to 
small sample sizes of subpopulations (e.g., among self-harm and assault encounters). 
The model covariates were generally nonsignificant, with some exceptions. Increasing age is 
negatively associated with odds of being diagnosed with anxiety disorders (OR: 0.98, 95%CI:0.97 – 
0.99), mood disorders (OR: 0.98, 95%CI: 0.97 – 0.99), and ‘other’ disorders (OR: 0.98, 95%CI: 0.96 – 
1.00). In terms of sex, relative to females, males were less likely to be diagnosed with anxiety disorders 
(OR: 0.59, 95%CI: 0.43 – 0.81) and depressed mood (OR: 0.55, 95%CI: 0.42 – 0.73), but more likely to 
be diagnosed with psychoses (OR: 1.79, 95%CI: 1.20 – 2.66). With respect to race and ethnicity, the only 
significant difference was that African Americans were significantly less likely to be diagnosed with 
‘other’ psychiatric disorders relative to Caucasians (OR: .26, 95%CI: 0.10 – 0.52). 
Table 2.4 presents estimates of covariates from the regression model. Insurance type is a 
significant predictor of manic mood and psychoses. The odds of diagnosed manic mood were higher for 
Medicare/Medicaid (OR: 2.27, 95%CI: 1.33 – 3.88) and other/unknown (OR: 2.11, 95%CI: 1.16 – 3.84) 
insurance types relative to private insurance. Similarly, the odds of diagnosed psychoses were higher for 
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Medicare/Medicaid insurance (OR: 3.27, 95%CI: 2.04 – 5.24) relative to private insurance. Encounters to 
a hospital in an MSA had increased odds of having a diagnosed manic mood (OR: 5.70, 95%CI: 1.84 – 
17.68) or psychoses (OR: 2.17, 95%CI: 1.34 – 3.51). Encounters occurring on the weekends were 
significantly less likely to result in a diagnosed depressed mood (OR: 0.74, 95%CI: 0.55 – 0.99) or 
psychoses (OR: 0.67, 95%CI: 0.46 – 0.98), relative to weekday encounters; no other differences by time 
of week were significant. Finally, the year of the encounter is significantly associated with increased odds 
of a diagnosed disorder for anxiety disorders, and psychoses, but no pattern is discernable.  
The regression-adjusted absolute risk, relative risk, and risk differences relative to unintentional 
injuries by disorder were presented in Table 2.5. For encounter due to self-harm, assault, and 
undetermined causes of injury, the risk of having a given psychiatric disorder is greater than the risk of 
the same disorder among encounters due to unintentional injuries. The relative risk describes the 
probability of being diagnosed with the disorder relative to unintentional injury encounters. For instance, 
the probability of being diagnosed with depressed mood in underdetermined injuries is 2.11 times greater 
than the probability of being diagnosed with depressed mood in unintentional injury encounters. 
In terms of absolute risk difference, 1.01% more of the sample had undetermined injury 
encounters diagnosed with depression compared to unintentional injury encounters. That is, the 
prevalence of depressed mood diagnoses in undetermined encounters is 1 percentage point greater than 
the prevalence of depressed mood diagnoses in unintentional injuries. The greatest difference in disorder 
prevalence occurred between self-harm encounters and unintentional encounters. These values should not 
be interpreted as tests of significance but can be used to conceptualize the results of the logistic regression 
models in more natural terms than ORs.  
 
Discussion 
This study examined the presence of diagnosed psychiatric disorders in ED patients presenting 
with injuries, and found evidence of effect measure modification35 by category of psychiatric disorder.  
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Table 2.3. Main effects estimates from multivariable logistic regression models examining the odds of being diagnosed with each category of the 
psychiatric disorder relative to not being diagnosed with the same disorder reported as odds ratios (ORs) with 95% confidence intervals (95% CIs).  
 Anxiety Disorders Depressed Mood Manic Mood Psychoses Other Disorders 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Injury Intent      
Unintentional ref. ref. ref. ref. ref. 
Undetermined 1.81 (1.22, 2.70) ♦ 1.79 (1.32, 2.43) ‡  1.04 (0.61, 1.79) 2.31 (1.59, 3.35) ‡  1.10 (0.45, 2.66) 
Assault 1.27 (0.60, 2.71) 1.65 (0.79, 3.43) 1.93 (0.94, 3.97) 1.31 (0.59, 2.94) 2.52 (0.76, 8.37) 
Self-harm 7.22 (4.16, 12.52) ‡  42.46 (30.04, 60.01) ‡  5.06 (2.87, 8.90) ‡  5.02 (2.25, 11.21) ‡  4.75 (1.15, 19.65) * 
Any Substance Use      
No ref. ref. ref. ref. ref. 
Yes 4.84 (3.25, 7.21) ‡  8.01 (6.15, 10.43) ‡  8.72 (5.68, 13.39) ‡  5.31 (3.66, 7.71) ‡  2.56 (1.34, 4.91) ♦ 
Comorbid Disorders      
Anxiety Disorder N/A 1.91 (0.96, 3.78) 2.88 (1.09, 7.59) * 1.97 (.71, 5.48) 6.00 (1.33, 26.94) * 
Depressed Mood 1.62 (0.82, 3.23) N/A 0.36 (.10, 1.21) 1.21 (0.48, 3.03) 6.37 (1.35, 30.07) * 
Manic Mood 2.51 (0.93, 6.78) 0.31 (0.07, 1.28) N/A 10.99 (4.95, 24.41) ‡  11.33 (2.98, 43.12) ‡  
Psychoses 2.19 (0.84, 5.69) 1.39 (0.56, 3.41) 10.45 (4.79, 22.80) ‡  N/A 3.20 (0.67, 15.28) 
Other Disorders 4.85 (1.08, 21.73) * 7.46 (1.89, 29.39) ♦ 11.11 (3.19, 38.8) ‡  2.79 (0.64, 12.28) N/A 
Notes:  ‡ p<0.001 ♦p<0.01  *p<0.05 
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Table 2.4. Covariate estimates from multivariable logistic regression models examining the odds of being diagnosed with each category of the 
psychiatric disorder relative to not being diagnosed with the same disorder reported as odds ratios (ORs) with 95% confidence intervals (95% CIs). 
 Anxiety Disorders Depressed Mood Manic Mood Psychoses Other Disorders 
 OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Centered Age .98 (.97, .98) <.001 .99 (.99, 1.00) .187 .98 (.97, .99) .004 1.01 (1.00, 1.02) .158 .98 (.96, 1.00) .028 
Sex           
Female ref.   ref.   ref.   ref.   ref.   
Male .59 (.43, .81) .001 .55 (.42, .73) <.001 .94 (.65, 1.34) .718 1.79 (1.20, 2.66) .005 .89 (.39, 2.06) .793 
Race & Ethnicity           
Caucasian Only ref.  ref.  ref.  ref.  ref.  
African American Only .74 (.43, 1.27) .279 .81 (.58, 1.13) .208 .98 (.65, 1.48) .937 1.28 (.87, 1.86) .207 .23 (.10, .52) <.001 
Hispanic Only 1.14 (.73, 1.78) .563 .80 (.50, 1.27) .343 .63 (.29, 1.37) .243 1.17 (.75, 1.84) .485 .33 (.10, 1.10) .072 
Other or Multiple  .62 (.25, 1.55)  .310 1.14 (.56, 2.28) .720 1.36 (.53, 3.49) .522 .79 (.32, 1.91) .597 1.35 (.30, 6.04) .696 
Insurance           
Private ref.  ref.  ref.  ref.  ref.  
Medicare/Medicaid 1.10 (.73, 1.65) .662 1.28 (.93, 1.76) .132 2.27 (1.33, 3.88) .003 3.27 (2.04, 5.24) <.001 2.17 (.86, 5.48) .102 
Self-Pay .81 (.49, 1.33) .403 .88 (.61, 1.29) .518 1.59 (.89, 2.84) .120 .77 (.43, 1.38) .384 .50 (.17, 1.49) .212 
Other/ Unknown 1.01 (.60, 1.69) .964 .86 (.58, 1.30) .480 2.11 (1.16, 3.84) .015 1.89 (.98, 3.66) .057 .82 (.24, 2.76) .745 
MSA           
No ref.  ref.  ref.  ref.  ref.  
Yes 1.07 (.62, 1.82) .813 1.02 (.65, 1.59) .931 5.70 (1.84, 17.68) .003 2.17 (1.34, 3.51) .002 1.80 (.31, 10.32) .509 
Time of Week           
Weekday ref.  ref.  ref.  ref.  ref.  
Weekend 1.05 (.78, 1.41) .744 .74 (.55, .99) .040 1.01 (.67, 1.50) .980 .67 (.46, .98) .040 .84 (.38, 1.82) .654 
Year of Encounter           
2007 ref.  ref.   ref.  ref.  ref.  
2008 2.13 (1.37, 3.29) .001 1.23 (.85, 1.77) .271 1.03 (.52, 2.04) .923 1.80 (.86, 3.77) .117 .40 (.09, 1.71) .218 
2009 .98 (.54, 1.78) .944 1.32 (.88, 1.99) .176 .79 (.39, 1.57) .494 1.94 (1.06, 3.57) .033 1.37 (.48, 3.92) .557 
2010 2.07 (1.22, 3.51) .007 1.01 (.64, 1.59) .967 1.31 (.68, 2.54) .422 1.88 (1.04, 3.42) .037 .42 (.13, 1.36) .150 
2011 1.77 (1.00, 3.15) .051 .99 (.68, 1.44) .969 .75 (.39, 1.45) .388 2.02 (1.23, 3.32) .006 1.43 (.55, 3.71) .467 
Notes:  ref. = reference group. 
          N/A = not applicable. 
          Non-injury encounters were omitted in this model. 
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Table 2.5. Estimate of effects as absolute risk (AR), relative risk (RR), and risk differences (RD) of any psychiatric disorder and by category of 
disorder controlling for regression results.  
Disorder 
Cause of Injury 
Unintentional  Undetermined  Assault  Self-harm 
AR % RR RD %  AR % RR RD %  AR % RR RD %  AR % RR RD % 
Any  2.737% 1 0  4.917% 1.796 2.179%  4.423% 1.616 1.686%  40.884% 14.935 38.146% 
                
Anxiety 0.563% 1 0  0.919% 1.630 0.355%  0.753% 1.337 0.190%  6.554% 11.631 5.990% 
Depressed Mood 0.917% 1 0  1.931% 2.105 1.014%  1.438% 1.567 0.520%  28.240% 30.783 27.323% 
Manic Mood 0.658% 1 0  0.855% 1.299 0.197%  0.825% 1.254 0.167%  5.506% 8.363 4.847% 
Psychoses 0.770% 1 0  1.403% 1.823 0.633%  1.581% 2.054 0.811%  5.613% 7.294 4.843% 
Other Disorder 0.168% 1 0  0.264% 1.577 0.097%  0.275% 1.640 0.107%  1.033% 6.163 0.865% 
Note:  Unintentional injury is the reference group
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After controlling for this modification, encounters due to self-harm injuries were more likely to have each 
category of psychiatric disorder relative to encounters due to unintentional injuries, while encounters for 
assault-related injuries were no more likely to be associated with psychiatric disorders. Similarly, 
encounters due to undetermined cause of injury were more likely to be diagnosed with anxiety disorders, 
depressed mood, and psychoses relative to encounters for unintentional injuries. 
While it is well-known that individuals who were victims of violence towards themselves or 
others were more likely to have a psychiatric disorder,36 it may be surprising that injuries with unclear 
causation have a higher probability of anxiety disorders, depression, and psychoses. For example, 
compared to unintentional injury encounters, undetermined injury encounters were 1.6 times more likely 
to have diagnosed anxiety disorders, 2.1 times more likely to have depressed mood, and 1.8 times more 
likely to have diagnoses psychoses. 
This is may be due to reluctance on the part of ED clinicians to classify ambiguous causes of 
injury as either intentional or unintentional, or more likely, an intentional misclassification to not to 
arouse negative connotations surrounding self-harm injuries. There is at least some anecdotal evidence 
that self-harm is frequently misclassified as undetermined intent,37-39 and it is even common practice in 
European injury research to consider undetermined injuries as self-harm injuries.40  
Given that injuries were easy to observe relative to psychiatric disorders, ED physicians should 
consider selectively screening high-risk injury patients (i.e., undetermined cause and self-harm injures) 
for anxiety disorders, depressed mood, manic mood, and psychoses. Screening ED patients for psychiatric 
disorders has been advocated and assessed by others.5,41,42 Several validated screening tools are available 
that do not require administration or interpretation by a psychiatrist or psychologist. Some examples of 
evidence-based assessments include the Patient Health Questionnaire (PHQ-9) for depression,43 CAGE 
AID for substance use,44 Mood Disorder Questionnaire (MDQ) for bipolar disorder,45 Generalized 
Anxiety Disorder (GAD-7) assessment for anxiety disorders,46 or Kessler 10 for general psychiatric 
health.47 A positive result from these screenings presents an opportunity for intervention that might be 
otherwise missed. Moreover, limiting the screening to only selected causes of injury may balance the 
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need to identify high-risk patients with the added burden of screening in EDs, which are already 
overburdened in terms of personnel, time, bed space, referral services, and money.  
There are several potential benefits of identifying patients with comorbid psychiatric disorders. 
First, identifying comorbid psychiatric disorders might detect a previously undiagnosed disorder, 
allowing the patient to obtain beneficial resources and potential treatment earlier in the course of the 
disorder. Diagnosing a psychiatric disorder should initiate the process of accessing additional inpatient or 
outpatient services depending on need. However, significant barriers would still exist after identification 
of a psychiatric disorder.48,49 Second, identifying patients at high risk of injury recidivism has implications 
for injury prevention efforts and reducing high utilizers of the ED.9 Third, diagnosing a psychiatric 
disorder present during an injury encounter may prevent death from future injuries. Previous work has 
shown that ED encounters for injuries often precede suicide, homicide, domestic violence, and 
perpetrating violence. Fourth, patients with untreated psychiatric disorders may be less compliant during 
treatment for injuries, which may lead return ED encounters, inpatient admission, longer stays, and higher 
costs.9,27,50 Therefore, screening patients for psychiatric disorders and referring patients who screen 
positive to a psychiatric specialist for further diagnosis can prevent a range of problems for the individual, 
the hospital, and society. 
 The study results did not support the hypothesis that an injury encounter in the ED is more 
strongly associated with a documented psychiatric disorder, relative to non-injury encounters to the ED. 
However, this may be due to effect measurement modification whereby the true effect is obscured by 
combining cause of injury categories. It is likely that the choice of control group (i.e., all non-injury ED 
encounters) diluted the relationship because encounters due primarily to psychiatric disorders are also 
included in the control group. Yet, the data supports the notion that most psychiatric disorders diagnosed 
during an ED encounter are not diagnosed in response to presentation of an injury. The second hypothesis 
assessed the relationship between assault-related injuries, self-harm injuries, and documented psychiatric 
disorders. The data partially supported this hypothesis. There is support for a strong, positive association 
for self-harm injuries and each category of documented disorders, but the evidence failed to support that 
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assault-related injuries are associated with specific psychiatric disorder categories. The lack of support for 
the association between assault-related injuries and specific disorders is likely due to an only small subset 
of the sample (n=77) having an assault injury and a psychiatric disorder. This analysis also partially 
supported the third hypothesis. Undetermined injury encounters are nearly twice as likely to also have a 
documented psychiatric disorder, generally, compared to unintentional injury encounters; however, when 
decomposed by category of psychiatric disorder, there is no difference in likelihood of manic mood and 
‘other’ disorders comparing undetermined and unintentional injury encounters. This suggests that that 
certain psychiatric disorders may increase the risk of injury, while other disorders have a negligible 
impact on risk of injury.  
Limitations 
There are important limitations to consider. First, these data are cross-sectional in nature and may 
not fully capture all information regarding the ED encounter and subsequent diagnosis or treatment. It is 
possible that latent psychiatric disorder or substance use is not diagnosed or recorded at the time of 
encounter or is not transcribed from the medical record to the NHAMCS dataset. The NHAMCS only 
provides for three diagnosis codes; therefore, if multiple diagnosis codes related to the injury are listed, 
secondary substance use or psychiatric disorder diagnoses may not have been reported. Such a case would 
result in an underestimation the prevalence of psychiatric disorder among injury patients, thus these 
findings should be considered conservative (i.e., underestimate the true relationship). Second, due to the 
cross-sectional nature of the data, causality could not be determined, nor could the temporal order of 
problems be determined. These data do not allow the assessment of whether the psychiatric disorder or 
substance use is the proximal cause of injury; however, it is unlikely that a psychiatric disorder would 
arise concurrently with an acute injury.  
Third, the dataset lacked detail regarding the severity of psychiatric disorder or injuries. However, 
inclusion of a diagnosis indicates enough salience to be documented during the ED encounter. Thus, 
psychiatric disorders posing significant problems are likely to be documented, while those not posing 
problems at the time of treatment are less likely to be documented. Finally, these data assume that 
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psychiatric disorders are diagnosed during care in the ED, but this implies that a clinician observed 
symptoms and diagnosed a disorder, or noted a potential disorder during the encounter, or the patient had 
an available medical history noting a chronic disorder. Given the estimated 4.0% of U.S. adults with 
serious psychiatric disorders51 and 18% of U.S. adults with any psychiatric disorders,52 one would expect 
the prevalence of documented psychiatric disorders to be higher than observed in the sample.  
 
Conclusion 
 Individuals presenting to the emergency department with undetermined and/or self-harm injuries 
are at significantly increased risk of having a psychiatric disorder, especially anxiety 
-related disorder, depressive and manic mood disorders, and psychoses. The presence of comorbid 
psychiatric disorders poses additional challenges to individuals with injuries, the healthcare system, and 
society, due to injury recidivism, longer hospital stays and costs, and death from future injury. Selectively 
screening injury patients potentially provides a missed opportunity to assist individuals in obtaining 
psychiatric health services and avert additional negative outcomes.  
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CHAPTER THREE: 
COST-BENEFIT ANALYSIS OF FIRST-LINE TREATMENT STRATEGIES FOR OBSESSIVE-
COMPULSIVE DISORDER IN CHILDREN AND ADOLESCENTS 
 
 
 
Introduction 
Obsessive-compulsive disorder (OCD) affects 1-2%, or 810,403 to 1,473,461, of U.S. children 
and adolescents (<18 years).1 The symptoms of OCD are typified by obsessions and/or compulsions. 
Obsessions are recurrent, persistent thoughts, impulses, or images that the individual identifies as 
intrusive and causing significant distress or anxiety.2 Compulsions are repetitive behaviors or mental acts 
that are completed in response to an obsession, to reduce feelings of anxiety, or according to rules.2 
Obsessive-compulsive symptoms can cause mild to severe problems3 and diminished quality of life.4 
Without treatment, most children and adolescents will experience chronic OCD lasting into adulthood.5,6 
Current treatment guidelines for OCD in children and adolescents recommend cognitive-
behavioral therapy (CBT) utilizing exposure and response prevention (ERP), and/or antidepressant 
medication (ADM) pharmacotherapy,7 either as monotherapies or concurrently. CBT is effective in 
reducing symptoms in children and adolescents with OCD, with effects superior to ADM monotherapy.8-
10 Additional studies have demonstrated the effectiveness of CBT combined with ADM therapy,8,10-12 
especially for higher severity patients.7,11,13 Currently, only five ADMs are Food and Drug Administration 
(FDA) approved for use in treating OCD in children and adolescents. These include the tricyclic 
clomipramine and the selective serotonin-reuptake inhibitors (SSRIs) sertraline, fluoxetine, fluvoxamine, 
and paroxetine.7,14,15 Citalopram is an SSRI that has not been approved by FDA for the treatment of child 
and adolescent OCD, but has been examined in open trials and clinical practice with evidence of 
effectiveness similar to other SSRIs.16,17  
Cost-effectiveness of evidence-based practices for child and adolescent OCD in the United States 
has yet to be examined.18 One previous study conducted in the United Kingdom (U.K.) found that CBT 
   
 
43 
 
was the most effective treatment and may be more cost-effective over time compared to SSRIs. However, 
the authors note that they were unable to definitively determine the most cost-effective treatment due to 
uncertainty in their model, and inclusion of low quality studies. Furthermore, the U.K. health system is 
vastly different from that of the U.S., including the ability to regulate price, access, and types of services 
provided. Therefore, this study was based on only data from vetted child and adolescent studies (i.e., 
peer-reviewed meta-analyses), and considers the U.S. healthcare system arrangement. Unfortunately, 
quality of life data for OCD treatments is severely lacking, therefore a cost-effectiveness analysis was not 
possible; however, a cost-benefit analysis (CBA) was employed instead.19  
The primary benefit of a CBA is the denomination in common units, change in symptom score, 
for all treatments, which can add more information for patients and providers when making treatment 
decisions. Cost-benefits may play a key role in treatment decisions, given that ADM monotherapy 
requires fewer visits resulting in lower costs in the short-term, but is less effective than CBT in the long-
term. However, CBT monotherapy is more effective relative to ADM long-term, but requires more visits 
and costs during the acute phase of treatment. Combined ADM+CBT may be the most effective, but 
costliest, treatment although findings have been inconsistent.11,19,20 While CBT tends to ameliorate OCD 
symptoms over the long- term, ADM must be continued indefinitely to control symptoms.21 Adults with 
OCD preferred ADM+CBT over CBT, and rated ADM monotherapy as least preferable.22,23 A study of 
parents showed that CBT was preferred over ADM+CBT, with ADM rated as least preferable 24 
In practice, there are a limited number of psychiatrists and psychologists that specialize in the 
treatment of child and adolescent OCD, which may limit treatment options in terms of geography and 
insurance coverage. Moreover, there is heterogeneity in terms of severity and treatment regimen in the 
trial data that can make application of the study results challenging for clinicians. For example, study 
samples vary by number and type of comorbid psychiatric disorders, the fidelity of CBT, and dosage of 
CBT and/or ADMs. These factors may influence the observed treatment effectiveness; thus, impacting 
study conclusions.  
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The purpose of this study is to compare the benefits, costs, and incremental cost-benefits for the 
three first-line treatments (1) CBT monotherapy, (2) ADM monotherapy, and (3) concurrent ADM+CBT 
and four follow-up strategies for augmenting treatment (1) more CBT after initial CBT, (2) adding CBT 
after initial ADM, (3) more ADM after initial ADM, and (4) adding ADM to initial CBT. Based on the 
lone previous CEA,25 it is hypothesized that CBT monotherapy will be the most cost-beneficial treatment 
strategy. The results of this study can be used to inform decision-making for payers, providers, patients, 
and their parents regarding optimum treatment of child and adolescent OCD. For example, payers may 
provide incentives to try the most cost-beneficial treatments first, while still allowing patients, parents, 
and doctors to select their preferred treatment. Similarly, if CBT were shown to be more cost-beneficial 
than SRIs, parents may use this evidence to advocate for this treatment for their children given their 
preferences.  
 
Methods 
Model Overview 
 Evaluation of the seven evidence-based7 treatment strategies for children and adolescents (5-17 
years) with OCD was conducted via Monte Carlo simulation. Model parameters were selected from 
probabilistic and deterministic parameters derived from the literature, and commercial insurance claims. 
These parameters were entered into a Monte Carlo simulation of 100,000 hypothetical, treatment naïve, 
children and adolescents with OCD, seeking first-line therapy, to estimate their benefits, costs, and 
incremental cost-benefits ratio (ICBR) for each of the seven treatment strategies. The analysis was 
conducted from the perspective of a commercial insurer in the United States and was implemented in 
TreeAge Pro 2018 R1.0 (Williamstown, MA). The overall model tree is presented in Figure 3.1
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Figure 3.1: Decision tree used to model cost-benefit analysis. 
Notes: Blue squares are decision nodes. Green circles are probability nodes. Red triangles are terminal 
nodes.  
The ‘#’ sign is software-based shortcut meaning the inverse of the opposing branch probability. 
ADM: antidepressant medication. 
CBT: cognitive-behavioral therapy. 
CYBOCS: children’s Yale-Brown Obsessive-Compulsive Scale. 
COMBO: concurrent ADM and CBT.  
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Parameters 
 This study included parameters from randomized control trials (RCTs) that examined the 
effectiveness of first-line treatment strategies in child and adolescent patients diagnosed with OCD. All 
studies were judged to be of high quality and providing sufficient information to aid in parameterization 
of the model for baseline and post-treatment effects. All included studies used similar treatment strategies 
and measures of effectiveness. Meta-analyses8,15,26 provided examples of high-quality RCTs that were 
subsequently used to derive the parameters. The full list of included parameters is given in Table 3.1.  
Treatment Effects and Benefits  
Treatment response was another source of heterogeneity among trials. This study, like all 
included trials, used the Children’s Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)27 to assess 
changes in disease state. The CY-BOCS is a tool used by clinicians to assess the symptom severity among 
children and adolescents. The CY-BOCS has been shown to be a valid, reliable, and sensitive to change in 
disease state for children and adolescents with OCD.27-30 The maximum possible score was 40, indicating 
extremely severe symptoms, and the minimum score was 0, indicating no problematic symptoms. 
Treatment effects were measured as the baseline score minus the post-treatment score for each treatment 
strategy. The average unit change in CY-BOCS and the associated distributions were obtained from the 
trials. Consistent with Storch et al.,31 treatment response was characterized as achieving a 25% reduction 
in CY-BOCS scores, and remission was defined as having a CY-BOCS score ≤14. 
There was not enough trial evidence for changes in quality of life in children and adolescents 
treated for OCD to denominate in quality adjusted life years (QALYs) as is common in CEAs.32,33 
However, CBAs use net change in outcome measure to denominate cost-effectiveness, when quality of 
life information was not available.34 The drawback to this method is the inability to compare cost-benefits 
across the gamut of health disorders, beyond OCD.   
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Costs 
The estimated costs were calculated using Medicare rates because they were readily available for 
all geographies in the U.S. and because the commercial insurance usually follows the cost trends set by 
Medicare.35 Outpatient treatment costs were calculated using the 2017 Medicare Physician Fee Schedule 
and multiplied by 130% to account for the average difference in nonsurgical payments between Medicare 
and private insurance.35 Healthcare Common Procedure Coding System (HCPCS) codes were used to 
determine the Medicare reimbursement rates for CBT (i.e., using general psychotherapy codes) and 
medication management visits. Psychotherapy visits consisted of 14 sessions lasting 60 minutes (HCPCS 
code 90837). The ADM monotherapy strategy consisted of 10 medication management visits (using the 
average of mild and moderate complexity; HCPCS codes 99212 and 99213) and 12 months of ADM 
therapy. The costs for ADM therapy were derived from commercial pharmaceutical claims. The cost for 
12 months was calculated as: 
𝐴𝐷𝑀 𝑌𝑒𝑎𝑟𝑙𝑦 𝐶𝑜𝑠𝑡 =  
∑
𝑇𝑜𝑡𝑎𝑙 𝐴𝑚𝑜𝑢𝑛𝑡 𝑃𝑎𝑖𝑑 𝑓𝑜𝑟 𝐴𝐷𝑀
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑑𝑖𝑠𝑝𝑒𝑛𝑠𝑒𝑑
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛𝑠
× 365 𝑑𝑎𝑦𝑠 
When summing estimates of cost, the standard deviation (SD) was calculated using Cohen’s pooled SD 
estimates.36 Finally, the costs of ADM+CBT was calculated as the sum of costs for ADM and CBT. The 
parameter estimates for costs are presented in Table 3.1. Despite not being able to calculate QALYs, the 
competing strategies were compared using the customary willingness-to-pay (WTP) thresholds of 
$50,00037 and  $100,000.38  
Interventions Assessed 
Current treatment guidelines recommend that CBT monotherapy be the first line treatment for 
mild to moderate cases, and that CBT be augmented with ADM in moderate to severe cases.7 Despite this 
recommendation, most clinicians surveyed failed to provide effective CBT in practice.7 Even among the 
trial evidence, there is heterogeneity in the total dose (i.e., visits × duration) of CBT, although the most 
common is 12 to 14 hour-long visits over 12 weeks.39,40 All included trials used very similar CBT 
protocols.41 ADM therapy consists of at least 6 to 12 months of medication use, in line with clinical 
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guidelines7 and in accordance with psychiatrists’ recommendations. The ADMs were grouped together 
because previous research showed no significant difference in treatment effects by medication.42  
Other medication augmentation strategies such as atypical antipsychotic and anticonvulsant 
medications were excluded from this analysis, because there are no RCTs for these medications in 
children and adolescents with OCD. Finally, combination ADM+CBT was assessed, because previous 
trials have found inadequate evidence of difference in response compared to CBT monotherapy.43,44 If a 
simulated individual did not remit following the first treatment arm, they could have one of following 
options: add CBT, add ADM, or in the case of combination therapy, maintain ADM+CBT. For example, 
if an individual received CBT in the first arm, but did not remit, then they would be randomly selected in 
to either CBT plus more CBT, or CBT adding an ADM. After this second treatment, an individual was 
classified as either remitting or refractory, with no additional treatment arms since there is no trial 
evidence to support treatment beyond this point.   
Monte Carlo Simulation 
A Monte Carlo simulation was constructed to determine the probabilistic CBA using the 
parameters described in Table 3.1. The simulation modeled 100,000 hypothetical children and adolescents 
aged 5 to 17 years. In each simulation iteration, each probabilistic parameter was randomly selected to 
account for variation and uncertainty in the model parameters (i.e., baseline CY-BOCS, changes in CY-
BOCS, and costs). After 100,000 iterations, the simulation results were used to calculate the effectiveness 
and cost estimates for each strategy. These effectiveness and cost estimates were used to calculate the 
ICBR from the commercial insurance payers’ perspective. The results were plotted in a scatterplot for 
dollars ($) versus benefits (unit change in CY-BOCS) in Figure 3.2. All analyses, including modeling, 
Monte Carlo simulation, and sensitivity analysis were conducted in TreeAge Pro 2017.  
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Table 3.1. Probabilistic and deterministic parameters used in the models.   
Measure Parameter Mean Value* SD* Distribution Source 
Baseline CY-BOCS  CY-BOCS at Initiation of Treatment 24.39 4.77 Normal 20,40,45-59 
      
Benefits 
(∆ in CY-BOCS) 
1) CBT monotherapy 12.58 6.11 Normal 20,40,45-59 
2) CBT, Non-remit, then more CBT 7.66 5.85 Normal 60 
3) CBT, Non-remit, then add ADM 9.45 6.90 Normal 60 
4) ADM monotherapy 7.65 6.51 Normal 45,52-59  
5) ADM, Non-remit, then more ADM 4.73 6.78 Normal 11 
6) ADM, Non-remit, then add CBT 11.22 6.68 Normal 11 
7) ADM + CBT concurrently 11.14 6.83 Normal 20,45 
      
Costs  
(2017$) 
CBT  $2372.02 $116.77 Gamma Author Calculation  
ADM‡ $1315.05 $503.10 Gamma Author Calculation  
ADM+CBT‡ $3687.07 $416.28 Gamma Author Calculation  
Notes:  SD = standard deviation 
* = calculated using Cohen’s formulas36 for pooled mean and pooled SD 
CY-BOCS = Children’s Yale-Brown Obsessive-Compulsive Scale  
CBT = cognitive behavior therapy; consisted of 14 sessions of 1-hour duration 
ADM = antidepressant medication  
‡ = 12-month course of ADMs and includes 10 medication management visits over 12 months. Medication costs calculated using Truven 
MarketScan Database. 
Non-remit: means non-remission, defined as a CY-BOCS score ≤ 14.  
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Probabilistic Sensitivity Analysis 
The robustness of the results was assessed using a probabilistic sensitivity analysis to model the 
uncertainty in the model parameters The distributions of the probabilistic and deterministic parameters 
were used to inspect the Monte Carlo simulation results, focusing on the variation in costs and 
effectiveness. Scatterplots of costs versus effectiveness (see Figure 3.3) and the confidence intervals for 
means of costs, effectiveness, and ICBRs were evaluated to determine which, if any, parameters exhibited 
sensitivity to variation. Due to lack of trial evidence, it was not possible to obtain the parameters for the 
probability of relapse into disease state, premature discontinuation of therapy, and estimates of excess 
mortality due to disease.61,62  
 
Results 
 The Monte Carlo simulated trial of 100 cohorts of 100,000 children and adolescents had a mean 
baseline CY-BOCS of 24.39 (SD: 0.48).  
 Benefits  
 The strategy using CBT monotherapy followed by adding ADM for non- or partial-responders 
resulted in the largest decrease in CY-BOCS score with a mean decrease of 16.25 (SD: 0.65) units. The 
ADM monotherapy strategy resulted in lowest decrease in CY-BOCS score (mean: 7.65, SD: 0.65). The 
simulated costs, benefits, and ICBR are summarized in Table 3.2. The change in CY-BOCS scores 
represents the average change from the baseline CY-BOCS until remission or after augmenting the initial 
strategy with CBT, ADM, or ADM+CBT, whichever came first.  
 Costs 
 The estimated costs of each treatment strategy are presented in Table 3.2. The lowest cost 
strategy was ADM monotherapy at $1,315.08. The highest cost strategy was concurrent ADM+CBT with 
an average cost of $3,687.13. 
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Cost-Benefits 
 The most cost-beneficial strategy was starting with CBT monotherapy, then adding ADM for 
refractory cases, despite not being the least expensive strategy. The cost-benefit ratios and ICBRs are 
presented in Table 3.2.The cost-benefit ratio for CBT monotherapy, followed by ADM for refractory 
cases, was $177.40, meaning it cost $177 per unit decrease in CY-BOCS. This was lower than all other 
strategies, except ADM monotherapy. Together ADM monotherapy and CBT monotherapy (followed by 
ADM) made up the cost-benefit frontier, above which strategies are dominated by those on or below the 
frontier curve.  
 Probabilistic Sensitivity Analysis 
 The PSA was performed after the Monte Carlo simulation to test the robustness of the simulation 
results. The plot representing 100 simulations, compares costs to effectiveness for all seven strategies. 
The results of the PSA support the conclusions drawn from the simulation; the plot (Figure 3.3) shows 
relatively tight clustering by treatment strategy, suggesting that the CBA results are reliable and valid. 
Figure 3.2. Graph of cost-benefit analysis results.
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Table 3.2. Cost-benefit results. 
Strategy Costs  
Mean 
Costs 
SD 
Incremental 
Costs 
Benefit  
(∆ CY-BOCS) 
Mean 
Benefit  
(∆ CY-BOCS) 
SD 
Incremental 
Benefit 
Incremental 
Cost Benefit 
Ratio (ICBR) 
Cost-
Benefit 
Ratio 
ADM monotherapy $1,315.08 $50.36 -- 7.65 0.65 -- -- $171.84 
ADM then more ADM $2,147.28 $106.82 $832.20 10.64 0.76 2.99 $278.16 $201.72 
CBT monotherapy $2,371.96 $11.67 $224.67 12.58 0.61 1.93 $116.17 $188.57 
ADM then add CBT $2,815.96 $125.79 $444.00 14.75 0.75 2.17 $204.49 $190.91 
CBT then add ADM $2,883.35 $72.28 $67.40 16.25 0.65 1.50 $44.84 $177.40 
CBT then more CBT $3,294.46 $117.01 $411.11 15.56 0.60 -0.70 -$590.70 $211.76 
ADM+CBT $3,687.13 $41.48 $803.77 11.14 0.68 -5.11 -$157.16 $331.01 
Notes: SD = standard deviation 
CY-BOCS = Children’s Yale-Brown Obsessive-Compulsive Scale  
CBT = cognitive behavior therapy 
ADM = antidepressant medication  
Benefits = unit change in CY-BOCS
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Figure 3.3. Probabilistic sensitivity analysis scatterplot. 
 
 
Discussion 
 This study produced the first CBA of competing first-line treatment strategies for treatment-naïve 
child and adolescent OCD in the United States. The results suggest that CBT monotherapy, augmented 
with ADM therapy, was the most cost-beneficial strategy and resulted in the largest decrease in CY-
BOCS score. These results are in general agreement with the only CEA of child and adolescent OCD, 
conducted in the United Kingdom,25 which found that strategies incorporating CBT were most cost-
effective overall. ADM monotherapy was the most cost-effective strategy at low willingness-to-pay 
(WTP) thresholds (i.e., <£15,000 or <$19,687), but at higher WTP thresholds, ADM+CBT was the 
optimal strategy.25 This study found that all treatment strategies were considerably less than either the 
$50,000 or $100,000 WTP thresholds commonly used in U.S.-based CEAs.37,38 
CBT mono, add ADM 
CBT mono 
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 Considering the study results, CBT monotherapy should continue to be the first-line therapy in 
children and adolescents with OCD, in accordance with published treatment guidelines.7 Even if patients 
eventually require augmentation with ADMs, it is more cost-beneficial to initiate CBT monotherapy first. 
These results also provide some support for the use of ADM monotherapy when CBT monotherapy is not 
clinically or logistically feasible. It should be noted, however, that the average difference in effectiveness 
was significantly greater for CBT and may be more likely to move patients into remission. It was 
surprising that ADM+CBT was not at least equally effective as CBT monotherapy, since both initiated 
CBT from the outset. This may be due to the small number of quality trials examining combined therapy, 
or due to the moderate baseline severity of children and adolescents evaluated in the ADM+CBT trials. It 
is possible that these results are due to a lack of consistent findings among children and adolescents with 
moderate OCD. As the clinical guidelines state,7 children and adolescents with more severe OCD may see 
better results with the ADM-augmented CBT compared to CBT monotherapy. Psychiatrists should weigh 
the findings of this CBA against severity, circumstances, and preferences of each patient and their 
parents. 
Limitations 
There were limitations to this study. First, since only two studies have examined quality of life 
concurrent to efficacy trials, it was not possible to calculate QALYs for the treatment strategies. This 
limits the generalizability and comparability of the findings to treatments of OCD to other disorders and 
treatments. Other studies have compared competing treatments for other disorders.34 Future RCTs should 
assess and report quality of life in children and adolescents so that QALYs can be calculated as an 
outcome. Second, this study was limited to published research, which may be subject to publication bias. 
The studies utilized to parameterize the model, represent high-quality RCTs and many have influenced 
current treatment guidelines. A register of trial results (with or without significant results) would help 
overcome this bias. Third, the studies were published are relatively heterogeneous in terms of comorbid 
disorders, dosage of CBT and/or ADM, and duration, but not in baseline CY-BOCS. The heterogeneity in 
these domains was largely balanced through the simulation and the models and may better represent the 
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true clinical population. The exception was in the case of severity, as most patients in the trials had a 
baseline CY-BOCS <30. As previously mentioned, these findings may not generalize to the most severe 
cases. Therefore, these results should be interpreted as the average effects, and costs, for treatment-naïve 
children, and not the expected results for all OCD patients. Fourth, this study was conducted from the 
perspective of the primary payer, which was assumed to be private insurance. The costs represented in 
this study were based on the average Medicare reimbursement rates since they are easily accessible, better 
understood, and often influence the reimbursement rates of private insurance. However, the true costs of 
care may vary by geography, provider, and insurer. Finally, the there is a paucity of literature on 
effectiveness of treatments in patients that remain refractory after trials of two frontline treatments. Due to 
this limitation, the present study was not able to determine the optimal strategy for patients that remained 
treatment refractory. 
 
Conclusion 
 This CBA found that CBT monotherapy, adding ADM therapy for refractory cases, was most 
cost-beneficial, followed by ADM monotherapy. The findings suggest that children and adolescents 
would derive greater benefit from high-quality, high-fidelity CBT compared to ADM monotherapy; 
however, not all patients have access to such care, in which case ADM monotherapy may be the best 
option. The results of this study represent the next iteration of evidence that can be used by patients, 
parents, providers, and policymakers when evaluating the most appropriate treatment for child and 
adolescent OCD. In addition, the evidence provided here supports the need to disseminate treatment 
guidelines and improve training for CBT more broadly within psychiatric specialists and pediatricians. 
The results of the study support the current evidence-based guidelines for the treatment of OCD in 
children and adolescents.  
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CHAPTER FOUR: 
THE ASSOCIATION BETWEEN COST-SHARING AND PSYCHOTHERAPY AND 
MEDICATION UTILIZATION AMONG ADULTS WITH OCD 
 
 
 
Introduction 
 The economics of health insurance has been a major subject of study for several decades, yet 
research examining price sensitivity to treatment modalities of specific disorders is limited. Patients are 
responsive to changes in the cost of health care and exhibit moral hazard when insured.1,2 Moral hazard 
incentivizes patients to use more health services than they would otherwise, because they are shielded 
from full cost of services received.3  Due to moral hazard, more unnecessary care and low-value care (i.e., 
services that do not contribute to better health, yet contribute to increased costs) are demanded by and 
provided to patients.3 There are two primary means of ameliorating moral hazard: 1) supply-side 
mechanisms targeting providers, and 2) demand-side mechanisms targeting patients. Managed care 
organizations use non-financial supply-side mechanisms such as prior authorization, narrow networks of 
providers, stepped-care requirements, medical necessity reviews, utilization reviews, and limits on 
number of covered encounters and services. However, passing on a portion of the costs to patients is one 
of the most common mechanisms for addressing moral hazard on the demand-side.4  
  Insurers impose some or all of  healthcare costs on patients through the use of cost-sharing, 
which can be one or more of the following mechanisms:5 a) deductible, which is the amount the patient 
must pay out-of-pocket before the insurer will pay for covered services; b) copayment, which is a fixed 
payment, due at the time of service and may vary by setting or provider; and c) coinsurance, which is a 
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percentage of the total negotiated costs paid by the patient after the patient reached their annual deductible 
limit. The relationship between these cost-sharing requirements can be complex, with varying levels  of 
cost-sharing by provider, setting, service, and medication class. For example, an encounter with a primary 
care provider may be subject to a copayment of $20, but an encounter with a specialist may be subject to 
a $50 copayment. Another example of variation involves encounters with providers and facilities under 
contracted rates (i.e., in-network) where the coinsurance is lower than encounters not under contracted 
rates (i.e., out-of-network). An insurer may use one or more of these cost-sharing mechanisms to 
disincentivize the use of low-value care.  
The demand for health services is relatively responsive to cost-sharing. The first empirical 
evidence of price-response comes from the seminal Rand Health Insurance Experiment (HIE) conducted 
from 1974-1982.6 The study found a price-elasticity of demand of -0.2 for all health services.7 This 
indicates that for each 10% increase in price, demand (as measured by total expense) would decrease by 
2%. More recently, Aron-Dine et al.8 reanalyzed the Rand HIE data using more modern analytic methods, 
which corroborated the original estimates of the price-elasticity of demand. However, the authors noted 
that the nonlinear nature of insurance benefit design creates challenges when estimating demand.8 This is 
because insurance plan benefits are designed to take advantage of patient sensitivity to price by varying 
the required cost-sharing to discourage the use of certain services or providers. Ideally, cost-sharing 
would encourage patients to restrict their use of unnecessary and low-value care, while not affecting their 
use medically-necessary care, despite relatively small increases in price.9  However, cost-sharing may 
inadvertently have an undesired effect on utilization of necessary and high-value services.  
Patient response to price varies by somatic and behavioral health. Early research has shown that 
behavioral health services are more sensitive to price than somatic health services,10-13 although, some 
have found this difference to be statistically nonsignificant.14,15 However, the overwhelming majority of 
research, including the Rand HIE, has found that behavioral health services are more sensitive to price 
than somatic health services, although the difference is not as large as originally thought.10,11,13,16-18 For 
example, the studies found that the price elasticity of demand for episodes of behavioral health services 
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varied from -1.0 to -0.4,10,11,13,16-18 compared to estimates of -0.2  for somatic health services.6-8,19 The 
variation in estimates may be due to the use of differing data sources (e.g., Rand HIE, national surveys, 
federal employee health plans, and surveys of providers), differences in encounter and episode 
definitions, differences in analytic methods, and differences in outcomes and covariates. Although the 
burden of evidence supports the notion that behavioral health services are more sensitive to price relative 
to somatic health services, the magnitude and robustness of the sensitivity to price across disorders and 
treatments is not well-understood.  
Variation in response to price may be moderated by the type of behavioral health services 
rendered.13,15,16,18,20-33 There are two primary treatment modalities for behavioral health disorders, 
psychotherapy and pharmacotherapy, which are effective for many disorders.34-36 Psychotherapy and 
pharmacotherapy are both widely available in the U.S., but the decision to initiate and continue either 
therapy is guided primarily by clinical need, and secondarily, by patient preferences.37 One of the chief 
concerns of patients is the cost of treatment.38-40 Accordingly, research examining the impact of cost-
sharing on behavioral health service utilization has shown some variation by treatment modality. Since 
psychotherapy and pharmacotherapy are often, but not always, substitutes, patients and providers may opt 
to utilize the lower-cost option. This is especially true since psychotherapy is subject to different cost-
sharing requirements than pharmacotherapy. Another consideration is the frequency at which patients 
incur costs due to treatment: psychotherapy involves weekly or bi-weekly encounters, whereas 
pharmacotherapy involves one office-based encounter and only monthly (or quarterly) prescription refills.  
There have been mixed findings regarding cost-sharing and the utilization of behavioral health 
services. One study found that the demand for behavioral health services is not significantly affected by 
differences in deductible, but demand was sensitive to differences in coinsurance, but only for patients in 
a fee-for-service plan.15 The same study also showed that coinsurance was not significantly associated 
with the probability of seeking care under a managed care plan, suggesting that other mechanisms were 
responsible for lower utilization, relative to fee-for-service plans.15 In addition, having an unmet 
deductible was associated with a lower probability of initiating and continuing psychotherapy for 
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depression, compared to individuals having met their deductible.41 However, copayment was not 
significantly associated with continuation of services after initiation.41  
Medication initiation and adherence, generally, decreases as cost-sharing increases. A review of 
132 articles describing the associations between cost-sharing, pharmaceutical coverage limits and 
requirements, and medical utilization, showed that for each 10% increase in cost-sharing, prescription 
drug spending decreases by 2% to 6%, varying by class of drug and disorders being treated.42 The review 
also found that drug switching from a brand to generic, or to a substitute medication was common for 
essential medications, while discontinuation was common for nonessential medications.42 Insurance plans 
that increase cost-sharing requirements for medications result in decreased initiation rates of 
antidepressants and decreased adherence rates for second-generation antipsychotics and other 
antidepressant augmentation medications.43-45  
Studies of the association of cost-sharing and utilization of behavioral health services have 
focused on depression, schizophrenia, and substance use, to the exclusion of other disorders. For example,  
patients with unmet deductibles were less likely to initiate psychotherapy for the treatment of 
depression.41 Another study found that Medicare patients with schizophrenia had 25-45% lower rates of 
use of non-psychiatrist therapy and case management compared to their peers without cost-sharing.46 
With regard to substance abuse services, reductions in cost-sharing requirements has been shown to 
significantly increase rates of initiation.47,48 
The lack of research regarding the association between cost-sharing and specific behavioral 
health disorders is problematic, because even privately-insured individuals face financial barriers to 
receiving health services.49,50 In light of this, this paper seeks to address this gap through the study of the 
association of cost-sharing on the utilization of outpatient behavioral health services and pharmacotherapy 
for the treatment of obsessive-compulsive disorder (OCD) among U.S. adults.  
Obsessive-compulsive disorder (OCD) affects approximately 1-2% of U.S. adults51,52 and can 
lead to reductions in quality of life53-55 and have negative impacts on relationships, employment, and 
emotional well-being.56,57 The symptoms of OCD include intrusive, unwanted, recurring thoughts 
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(obsessions) and repetitive behaviors or mental acts (compulsions) that are performed to reduce distress 
associated with the preceding obsessive thoughts.58 The recommended first-line treatments for OCD are 
cognitive-behavioral therapy (CBT) and/or serotonin reuptake inhibitors (SRIs),58 both of which have 
shown to be effective interventions.59-64 Despite the existence of these effective treatments, there are few 
economic studies focusing on OCD65 and no studies examining the association between cost-sharing and 
utilization of OCD treatments.  
This chapter assesses the association between cost-sharing and utilization of outpatient 
psychotherapy encounters and adherence to SRIs for among privately-insured adults with a claim for 
OCD. Utilization is operationalized as treatment intensity, which is the count of encounters in a treatment 
episode.17,20,22,66 It is hypothesized that patient cost-sharing requirements (i.e., percent of total charges) are 
inversely associated with intensity of outpatient psychotherapy encounters, controlling for covariates. 
Simply counting the number of provider contracts is a poor estimate of service quality;67 thus, the total 
dose of psychotherapy received, in minutes,  is used to help overcome this limitation. The 2008 American 
Psychiatric Association guidelines recommended 13 to 20 psychotherapy sessions for a total of 25 hours 
(1,500 minutes).58 It is hypothesized that cost-sharing is inversely associated with total dose of 
psychotherapy (in minutes), controlling for covariates. Finally, the association between cost-sharing and 
SRI adherence is assessed since SRI medications are an important treatment modality for OCD and may 
contribute to improved psychotherapy continuance. Consistent with previous research,42,68,69 it is 
hypothesized that patient cost-sharing (i.e., the percent of total episode cost) is negatively associated with 
adherence to SRIs, controlling for covariates. This chapter presents new knowledge of the associations 
between cost-sharing and use of psychotherapy and/or pharmacotherapy among U.S. adults with OCD. 
 
Methods  
Data Source 
The data was abstracted from the 2008 to 2010 Truven MarketScan Commercial Claims and 
Encounters dataset. The dataset contains information for inpatient, emergency, outpatient, and 
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pharmaceutical health insurance claims for around 100 of the payers, including commercial insurers, Blue 
Cross/Blue Shield plans, and third-party administrators.70 Most of the employers were self-insured plans 
regulated under the Employee Retirement Income Security Act of 1974 (ERISA).70 Altogether, the claims 
represent about 19.5 million covered lives across 3 years, including employees, retirees, spouses, and 
their dependents. Individuals were tracked longitudinally and across settings using an anonymous, unique 
identifier. This dataset represents one the largest claims-based datasets available for research in the U.S. 
In addition, the individuals observed in the dataset are more homogenous than other research studies that 
include all payers.15,25,71-73 Since all individuals have private insurance through employment, it is unlikely 
that any would qualify as below the poverty level. This study was approved under expedited review by 
the University of South Florida institutional review board.  
 The dataset was delivered as post-adjudicated claim lines by enrollee by year, which provided 
one procedure, up to two diagnoses, and all associated provider, patient, and financial information per line 
(table row). Claim lines were provided in one of three mutually-exclusive tables based on Truven-
determined location of treatment: inpatient, outpatient, or pharmaceutical. A claim is constructed by 
grouping all claim lines with the same date for the same provider. A claim is synonymous with an 
encounter in this chapter. Claims could further be aggregated by enrollee, family, year, or any other 
variables contained herein.  
Unit of Analysis 
Consistent with previous research,20,22,67,74,75 encounters were grouped into episodes of care by 
enrollee. An episode of care was operationalized as a series of outpatient OCD-related encounters with no 
more than a 90-day gap in consecutive encounters, which represented a treatment discontinuation. Index 
encounters and subsequent encounters were determined by claim lines with a primary ICD-9-CM code 
(‘300.3’) for OCD. This method of attributing encounters to a diagnosis has been previously 
demonstrated in the same dataset examining depression76 and eating disorders.66 Outpatient encounters 
were determined by examining the place of service code, rather than the Truven-generated tables, because 
emergency department encounters were classified as outpatient if not admitted, and inpatient if admitted. 
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All psychotherapy and medication management encounters “sandwiched” between OCD-related 
encounters were included since it was likely that OCD symptoms were addressed during these intervening 
encounters, despite OCD not being recorded as the primary diagnosis code. This was done to balance the 
conservative approach of including only OCD-related psychotherapy encounters with the more liberal 
approach of including any psychotherapy encounters.  
Upon initial aggregation of encounters into episodes, the year, eligibility, and missing data were 
ignored to attribute encounters to the appropriate episode. After grouping, episodes with missing data 
were excluded from the analysis to ensure that only complete episodes were included. To mitigate 
inclusion of episodes where discontinuation was due to lack of insurance coverage, enrollees had to 
maintain insurance coverage 90 days before index encounter, throughout the episode, and 90 days after 
the last encounter. If insurance coverage lapsed for any amount of time during these periods, the entire 
episode was excluded. If any encounters within an episode spanned more than one calendar year, the 
entire episode was excluded, because insurance benefits typically reset January first each year,71 which 
could result in dramatic changes in cost-sharing within the episode. However, excluding episodes that 
span years reduces the generalizability of this study because it does not follow the natural course of 
disease (i.e., not defined by calendar time). More specifically, the exclusion of episodes that span years 
accentuates the seasonality effects, which were adjusted using year and month of episode initiation in the 
models.  
Pharmaceutical claims for a SRI, as determined by the National Drug Code (NDC), were matched 
by enrollee ID number, and included if they occurred on or after the index OCD-related encounters and 
until a 90-day gap without medication or the end of the year, whichever occurred first. Claims for the 
following SRIs were included: clomipramine, citalopram, escitalopram, fluoxetine, fluvoxamine, 
paroxetine, sertraline. In the absence of head-to-head trial evidence, all SRIs were grouped together due to 
very similar neurobiological effects.77,78  
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Inclusion Criteria 
The study sample included only adults aged 18 to 64 years. Only claim lines that provided fee-
for-service (FFS) or equivalent financial information were included in the analysis. Claims billed under 
capitation without FFS equivalents were excluded due to lack of treatment and cost-sharing detail 
necessary for analysis. Table 4.1 describes how the sample size changed as the unit of analysis was 
constructed, inclusion criteria was applied, and observations with missing values were removed.  
 
Table 4.1. Sample size, analytic units, and data manipulation at each stage of sample construction.  
 Stage Operation Units Sample 
Size 
Deletions  
n (%) 
1 Adults with 
Primary OCD 
Initial Sample Claim lines 283,401 -- 
2 Fee-for-service 
plans 
Remove lines with capitated 
payments 
Claim lines 254,996 28,405 (10.0) 
3 Unique claim lines Remove duplicates Claim lines 243,487 11,479 (4.5) 
4 Insurance eligibility  Remove observations outside 
enrollment window, OR 
missing enrollment data 
Claim lines 232,696 10,791 (4.4) 
5 Create initial 
episodes  
Aggregate claim lines into 
episodes 
Episodes 42,716 --  
6 Only Episodes 
contained within a 
Calendar Year 
Remove Episodes that span 
calendar years  
Episodes 27,323 15,393 (36.0) 
7 Finalize episode 
creation 
Remove episodes missing 
essential variables 
Episodes 27,301 22 (<0.1) 
8 Only Episodes with 
non-negative 
financial variables 
Remove episodes where sum 
of financial variables is 
negative 
Episodes 27,099 202 (0.7) 
9 Final Sample Remove episodes with missing 
values for regression variables 
Episodes 26,043 1,056 (3.89) 
10 Pharmacotherapy 
Subsample 
Remove episodes without an 
SRI claim 
Episodes 16,205 9,838 (37.78) 
 
 
Dependent Variables 
Psychotherapy Intensity and Dose 
Treatment intensity was defined as the count of psychotherapy encounters within an episode of 
treatment.28,79-82  Psychotherapy encounters identified by 2008-2010 CPT codes (90804', '90816', '90806', 
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'90818', '90847', '90808',' 90821'). The total dose of psychotherapy was examined by summing the number 
of encounters multiplied by the duration of the encounter as determined by the CPT billing codes. The 
code definitions and operationalization are presented in Table 4.2 below. The total amount time spent in 
psychotherapy has been previously used to study treatment intensity.61,83 Medication management 
encounters were determined by a CPT code of ‘90836’.  
 
Table 4.2. Psychotherapy code definitions and duration of encounters. 
Code CPT Billing Code Definition Operational Definition 
90804 20-30 minutes of outpatient psychotherapy 30 minutes of psychotherapy 
90816 20-30 minutes of inpatient psychotherapy 
90806 45-50 minutes of outpatient psychotherapy 50 minutes of psychotherapy 
90818 45-50 minutes of inpatient psychotherapy 
90808 75-80 minutes of outpatient psychotherapy 80 minutes of psychotherapy 
90821 75-80 minutes of outpatient psychotherapy 
90847 Family psychotherapy with patient present 50 minutes of psychotherapy 
90836 Pharmacologic management, including 
prescription, use and review of medication with 
no more than minimal medical psychotherapy 
No psychotherapy; medication 
management only 
 
  
SRI Medication Adherence  
Only the recommended first-line pharmacotherapy for OCD, SRIs, were examined.65,84-86 As 
previously mentioned, specific formulation with each of these ingredients was determined from the NDC 
and RED BOOK™ information. The RED BOOK is a propriety digest that provides detailed drug 
information and wholesale pricing of nearly all prescription, over-the-counter drugs, and nutraceuticals.87 
The dependent variable for pharmacotherapy utilization was adherence, but because adherence is poorly 
defined and enumerated, the modified medication possession ratio – modified (MPRm) was used as a 
proxy measure of adherence. This metric has been previously validated in other pharmaceutical 
research.88-90 It was operationalized by: 
𝑀𝑃𝑅𝑚 =  
𝑡𝑜𝑡𝑎𝑙 𝑑𝑎𝑦𝑠′𝑠𝑢𝑝𝑝𝑙𝑦 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑆𝑅𝐼𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑆𝑅𝐼𝑠
𝐿𝑎𝑠𝑡 𝑓𝑖𝑙𝑙 𝑑𝑎𝑡𝑒 − 𝑓𝑖𝑟𝑠𝑡 𝑓𝑖𝑙𝑙 𝑑𝑎𝑡𝑒 + 1 𝑑𝑎𝑦 + 𝑙𝑎𝑠𝑡 𝑓𝑖𝑙𝑙 𝑑𝑎𝑦𝑠′𝑠𝑢𝑝𝑝𝑙𝑦 
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Since all SRIs were treated equivalently, any combination of SRIs during the study period was 
counted towards the MPRm. For example, switching from one medication was not penalized, and the 
enrollee would be considered covered by SRI for the sum of the days’ supply. The denominating period 
was defined as the date of the first prescription fill until the last fill date of the episode. The value of 
MPRm could range from 0 to >1.0, with 0 representing no prescriptions filled (although, this is 
technically not possible in this study due to inclusion criteria), a value of 1.0 representing a medication 
available for each day, and a value >1.0 meaning the enrollee had more medication dispensed than days in 
the period. Values above 1.0 were truncated at 1.0 since patients could not, in practice, be more than 
100% adherent and values above 1.0 only serve to artificially inflate the MPRm. In accordance with 
previous work89-94 and analytic guidelines,95 an enrollee was considered adherent if they had an MPRm 
≥0.80. The last prescription filled in an episode (i.e., discontinuation) was determined by a gap of 90 days 
without a medication refill claim after the supply had been exhausted.45,96   
Independent variables 
Cost-sharing was the explanatory variable of interest in this study. Consistent with previous 
research,72,97,98 cost-sharing was operationalized the enrollee’s percent share of total encounter and 
medication costs incurred for all OCD claims during the episode. Operationalizing cost-sharing in this 
way provides a method of comparing plans with varying levels of copayment, coinsurance, and 
deductibles. The most common method to examine cost-sharing policies in previous research was 
difference-in-difference or similar design following a modification of insurance benefits for all or a subset 
of enrollees.4,18,22,23,30,32,99-102 This approach requires information about the defined benefits, in addition to 
enough observation time before and after the change to power the analysis. In this chapter, no clear 
change in benefits occurred, and plan information was not available from the dataset owner. An 
alternative approach, described in detail in the Methods section, was employed. The benefit of this 
approach is that it takes advantage of existing heterogeneity in plan structures across a wide array of 
employers and insurers. The disadvantage of this approach is lack of control group and data specificity to 
draw more causal conclusions. 
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 Cost-sharing was calculated as the sum of all copayments, coinsurance, and deductibles divided 
by the sum of payments made for encounters and medications. The denominator includes all the 
numerator payments (if any), plus payments made by the insurer. Episodes with no payments or negative 
payment values were excluded from the analysis because these could not be explained.  
 % 𝑐𝑜𝑠𝑡 𝑠ℎ𝑎𝑟𝑒 =  
𝐶𝑜𝑝𝑎𝑦𝑚𝑒𝑛𝑡𝑠 + 𝑐𝑜𝑖𝑛𝑠𝑢𝑟𝑎𝑛𝑐𝑒 + 𝑑𝑒𝑑𝑢𝑐𝑡𝑖𝑏𝑙𝑒
𝑡𝑜𝑡𝑎𝑙 𝑒𝑛𝑐𝑜𝑢𝑛𝑡𝑒𝑟 𝑝𝑎𝑦𝑚𝑒𝑛𝑡𝑠 + 𝑆𝑅𝐼 𝑝𝑎𝑦𝑚𝑒𝑛𝑡𝑠 𝑓𝑜𝑟 𝑒𝑝𝑖𝑠𝑜𝑑𝑒
∗ 100 
 Copayment is the predetermined flat-rate amount paid by the enrollee to the provider at the time of 
service. Coinsurance is defined the amount that the enrollee paid to the provider, usually as a percentage 
of the total claim charges. The deductible refers to the amount that a patient must pay out-of-pocket 
before any insurance coverage applies. A separate variable, family deductible, was included to indicate 
the total amount the enrollee and their family (i.e., spouse and dependents) had paid towards their 
deductible for all outpatient and inpatient care (for all disorders, including previous OCD) up to the index 
OCD encounter, excluding the amount paid for the index encounter. This variable sought to control for 
the lack of information about the deductible limit and address the differences in utilization between 
individuals who met their deductible versus those who did not.41,99  
Covariates 
The multivariate models also controlled for other covariates common to the cost-sharing and 
behavioral disorder utilization literature.15,20,22,47,67 Available patient demographics included sex (male or 
female), age (restricted to 18 to 64 years in this study), and whether the patient was an employee, retiree, 
spouse or dependent. Patient race and ethnicity was unavailable, as is the case with most claims-based 
analyses.15,20,67 Unfortunately, additional information pertaining to socioeconomic information was 
unavailable and could not be reasonably approximated using census data due to a lack of geographic 
resolution (e.g., metropolitan statistical areas was the most detailed information available). Comorbid 
conditions were assessed using the Charlson Comorbidity Index (CCI), which has been used in previous 
health insurance claim research.103-105 The index represents the count of 17 chronic diseases for which the 
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enrollee had a previous or concurrent diagnosis or procedure. Because the CCI does not include 
behavioral comorbidities, a count of behavioral comorbidities was created by using the Clinical 
Classification Software106 to identify classes of behavioral disorders, excluding OCD.   
Dummy variables (i.e., 1 or 0) were created to represent levels of categorical variables. Insurance 
type was included to control for differences in management techniques that might confound the 
relationship between cost-sharing and utilization. The types of insurance arrangements in the dataset were 
health maintenance organizations (HMOs), preferred provider organizations (PPOs), exclusive provider 
organizations (EPOs), point of service (POS) with or without capitation, patient directed health plans 
(CDHPs), and high-deductible health plans (HDHPs). A categorical variable was used to describe if the 
enrollee resided in the Northeast, Midwest, South, or West regions. An indicator for whether a patient 
lived in a metropolitan statistical area (MSA) or not was assessed as a proxy for urban vs. rural, since 
individuals living in rural areas have less access to behavioral services.73,82,107,108 However, in preliminary 
analyses and regression analyses, there was no association between utilization and this measure, so it was 
excluded in final models. 
Analytic Plan 
 The unit of analysis, episode, was constructed as described above, and used in all analyses. Mean 
and standard deviation (SD) were calculated for continuous variables and count and percentage were 
calculated for categorical variables. The descriptive statistics for dependent and independent variables are 
presented in Tables 4.2-4.5. 
The distributions for psychotherapy intensity and dose exhibited large clusters of values at zero, 
representing individuals who did not receive any psychotherapy. It was assumed that the decision to 
initiate and the decision to continue were from similar, but not identical processes. Therefore, zero-
inflated negative binomial (ZINB) regression models17,72,92,96 were used to estimate the association 
between cost-sharing and psychotherapy intensity, and between cost-sharing and psychotherapy dose, 
controlling for type of insurance plan, use of SRIs at any time during treatment, CCI, count of comorbid 
behavioral disorders, age, sex, and region. A series of models for each dependent variable shows the 
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effects of adding covariates to the model sequentially. The standard errors (SEs) were adjusted for 
clustering within families to account for unobservable endogeneity. 
The logit portion of the models, or the portion that estimated the odds of having at least one 
encounter, was held fixed across all models for both psychotherapy intensity and dose since they were 
assumed to be part of the same decision process. The underlying logit equation was: 
𝑙𝑜𝑔𝑖𝑡(𝑐𝑜𝑢𝑛𝑡 > 0) = 𝛽1𝑒 ∗ 𝑐𝑜𝑠𝑡𝑠ℎ𝑎𝑟𝑒 + 𝛽2𝑒 ∗ 𝑝𝑙𝑎𝑛𝑡𝑦𝑝𝑒 + 𝛽3𝑒 ∗ 𝑐𝑜𝑠𝑡𝑠ℎ𝑎𝑟𝑒 ∗ 𝛽4𝑒 ∗ 𝑝𝑙𝑎𝑛𝑡𝑦𝑝𝑒 +
 𝛽5𝑒 ∗ 𝑦𝑒𝑎𝑟 + 𝛽6𝑒 ∗ 𝑚𝑜𝑛𝑡ℎ +  𝛽7𝑖 ∗ 𝑝𝑠𝑦𝑐ℎ𝑖𝑎𝑡𝑟𝑖𝑐 𝑐𝑜𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑖𝑒𝑠 + 𝜀  
Where e denotes the variable was measured at episode-level, i denotes the variable was measured at the 
individual level, and ε represents the error term. The negative binomial equations describe the log count 
of encounters and minutes of psychotherapy. Both models were built-up from the simplest model in 
which cost-share was regressed on the respective dependent variable. Table 4.3 shows the iterative 
process used to build up the models and check stability of estimates. The negative binomial specification 
of the full model is given by: 
𝑁𝐵 (utilization) = 𝛽1𝑒 ∗ 𝑐𝑜𝑠𝑡𝑠ℎ𝑎𝑟𝑒 + 𝛽2𝑒 ∗ 𝑝𝑙𝑎𝑛𝑡𝑦𝑝𝑒 +  𝛽3𝑒 ∗ 𝑦𝑒𝑎𝑟 + 𝛽4𝑒 ∗  𝑚𝑜𝑛𝑡ℎ + 𝛽5𝑒 ∗
𝑝ℎ𝑎𝑟𝑚𝑐𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑦 + 𝛽6𝑖 ∗ 𝐶𝐶𝐼 + 𝛽7𝑖 ∗  𝑝𝑠𝑦𝑐ℎ𝑖𝑎𝑡𝑟𝑖𝑐 𝑐𝑜𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑖𝑒𝑠 + 𝛽8𝑖 ∗ 𝑎𝑔𝑒 +  𝛽9𝑖 ∗ 𝑓𝑒𝑚𝑎𝑙𝑒 +
𝛽10𝑖 ∗ 𝑟𝑒𝑔𝑖𝑜𝑛 + 𝜀  
 
Table 4.3. Process for building-up zero-inflated negative binomial models for psychotherapy intensity 
and dose. Variables entered into the negative binomial equations. 
Model Covariates regressed on psychotherapy intensity and psychotherapy dose 
1 Cost-share 
2 Cost-share + plan type 
3 Cost-share + plan type + year + month  
4 Cost-share + plan type + year + month +SRI used 
5 Cost-share + plan type + year + month +SRI used + CCI + psychiatric comorbidities 
6 Cost-share + plan type + year + month +SRI used + CCI + psychiatric comorbidities + 
enrollee age + female  
7 Cost-share + plan type + year + month +SRI used + CCI + psychiatric comorbidities + 
enrollee age + female + region 
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 Because coefficients for ZINB models are difficult to interpret, average marginal effects (AMEs) 
were estimated post-regression. The SEs for the AME estimates were also adjusted for clustering by 
family. The AMEs are presented as the estimates for the regression analyses in Tables 4.9 and 4.10, and 
the ZINB coefficient estimates can be found in Tables A4.1 and A4.2 in the Appendix.  
The subset of episodes with at least one SRI fill was examined using a logistic regression models 
to assess the association between SRI adherence and cost-sharing, controlling for type of insurance plan, 
use of psychotherapy during the episode, comorbidities (CCI), count of comorbid behavioral disorders, 
age, sex, and region. The logit model was specified as: 
𝑙𝑜𝑔𝑖𝑡(𝑀𝑃𝑅𝑚 ≥ 0.80) = 𝛽1𝑒 ∗ 𝑐𝑜𝑠𝑡𝑠ℎ𝑎𝑟𝑒 + 𝛽2𝑒 ∗ 𝑝𝑙𝑎𝑛𝑡𝑦𝑝𝑒 + 𝛽3𝑒 ∗ 𝑚𝑜𝑛𝑡ℎ + 𝛽4𝑒 ∗ 𝑦𝑒𝑎𝑟 +
𝛽5𝑒 ∗ 𝑝𝑠𝑦𝑐ℎ𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑦 + 𝛽6𝑖 ∗ 𝐶𝐶𝐼 + 𝛽7𝑖 ∗ 𝑝𝑠𝑦𝑐ℎ𝑖𝑎𝑡𝑟𝑖𝑐 𝑐𝑜𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑖𝑒𝑠 + 𝛽8𝑖 ∗
𝑝𝑠𝑦𝑐ℎ𝑖𝑎𝑡𝑟𝑖𝑐 𝑐𝑜𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑖𝑒𝑠 + 𝛽9𝑖 ∗ 𝑎𝑔𝑒 + 𝛽10𝑖 ∗ 𝑓𝑒𝑚𝑎𝑙𝑒 + 𝛽11𝑖 ∗ 𝑟𝑒𝑔𝑖𝑜𝑛 + 𝜀  
The process for building up the logistic model is shown in Table 4.4. The dependent variable was 
dichotomized as adherent (MPRm ≥0.80) and nonadherent (MPRm <0.80) in keeping with previous work 
and recommendations.89-94  A sensitivity analysis was performed with alternative dichotomization 
thresholds (i.e., MPRm ≥0.50, MPRm ≥0.60, MPRm ≥0.70, MPRm ≥0.90, MPRm ≥0.95) to examine the 
stability of the logit estimates. The results for all logistic models are presented in Appendix Table A4.3 
and sensitivity analysis in Appendix Table A4.4. The regression coefficient SEs were adjusted for 
clustering by family. The AME estimates were calculated post-regression and presented in the primary 
findings in Table 4.11. All estimates were evaluated at for α = 0.05.  All analyses were completed in Stata 
15 (College Station, TX). 
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Table 4.4. Process for building-up logistic regression models for MPRm. 
Model Covariates regressed on MPRm 
1 Cost-share 
2 Cost-share + plan type 
3 Cost-share + plan type + any psychotherapy use 
4 Cost-share + plan type + any psychotherapy use + year + month  
5 Cost-share + plan type + any psychotherapy use + year + month + CCI + psychiatric 
comorbidities 
6 Cost-share + plan type + any psychotherapy use + year + month + CCI + psychiatric 
comorbidities + enrollee age + female  
7 Cost-share + plan type + any psychotherapy use + year + month + CCI + psychiatric 
comorbidities + enrollee age + female + region 
 
Results 
 
 There are 26,043 episodes of treatment for OCD contributed by 17,344 unique enrollees. 
Episodes encompass an average of 3.1 (standard deviation [SD]: 5.1) encounters, which is lower than 
previous work (mean range of encounters: 4-10).10,73,82,109,110 Episodes last an average of 29.9 (SD: 54.4) 
days, which is on the low end of  range found in previous work (range of mean days: 21-582).81,111 There 
is an average of 1.2 (SD: 3.3) psychotherapy encounters, for a total average dose of 60.6 (SD: 170.7) 
minutes of psychotherapy, and 0.5 (SD: 1.0) medication management encounters. This was low relative to 
previous research on utilization for psychotherapy, where the mean number of psychotherapy encounters 
conditional on any use was  between 10101 and 1566 encounters. There are 16,205 episodes that had at least 
one claim for an SRI. The average number of SRIs used during a single episode is 1.1 (SD: 0.3) with a 
mean MPRm of 0.77 (SD: 0.2), which was in line with previous adherence research.89,100,112 The 
descriptive statistics for episode characteristics are found in Tables 4.5 to 4.8.  Table 4.5 presents 
descriptive statistics for the continuous or semi-continuous dependent and independent variables. The 
distributions of all variables in Table 4.5, except age (which has a moderate skew) show a strong positive 
skew as evidenced by histograms in Figures 4.1 to 4.4.  
The primary variable of interest, episode cost-sharing, is positively skewed (see Figures 4.5 and 
4.6), with a moderate increase at the tail of the distribution. The mean cost-share is 34% of episode costs 
or about $120 out-of-pocket. Three-quarters of the episodes are associated with cost-sharing of less than 
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45% of episode costs or about $125 overall. There is a large number of individuals with zero cost-sharing 
as one might expect from insurance benefit design; however, the top end of the distribution is 100% cost-
sharing or over $7,700 out-of-pocket. Upon initiation of the episode (index encounter) the amount paid 
towards the family deductible averages $271.28, while the total out-of-pocket costs for all care is over 
$700.  
 
 
Figure 4.1. Histogram showing the number of episodes in the sample.  
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Figure 4.2. Histogram showing skewed distribution of all encounters per episode with mass at one. 
 
 
 
Figure 4.3. Histogram showing the distribution of psychotherapy intensity with mass at zero.  
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Figure 4.4.  Histogram showing the distribution of Medication Possession Ratio-modified, in which 
ratios > 1 were limited to 1. Note the positive skew and mass at 1. 
 
 
 
Figure 4.5. Histogram showing cost-share as a percentage of total cost of care for OCD per episode. The 
spikes represent cost-sharing of 0%, 10%, 20%, 50% and 100%, which are common to insurance benefit 
design. 
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Figure 4.6. Histogram showing cost-share as a dollar amount for OCD treatment during an episode. Note 
the negatively-skewed, and over-dispersed distribution with mass at $0. 
 
 
 
Table 4.5. Continuous and semi-continuous episode characteristics. Total n =26,043 encounters. 
Variable  Mean SD Min 25
th 
% Median 75
th
 % Max 
Total Encounters (n) 3.02 5.05 1 1 1 3 183 
Psychotherapy Encounters 
(n) 
1.20 3.35 0 0 0 1 83 
Psychotherapy Dose (min.) 60.60 170.7 0.00 0 0 50 4150 
Medication Mgmt. 
Encounters 
0.50 0.97 0.00 0 0 1 31 
MPRm  0.79 0.20 0.04 0.64 0.81 0.94 1.00 
Episode Cost-Share ($) $120.17 $231.77 $0 $25.00 $55.00 $122.65 $7,723.38 
Episode Cost-Share (%) 34.00 25.42 0 16.59 27.43 44.53 100.00 
        
Total Episodes (n) 1.86 1.31 1 1 1 2 11 
Family Deductible at index $269.95 $489.01 $0 $0 $15.40 $364.30 $9,046.28 
Family OOP at index $697.26 $1,061.46 $0 $60.44 $300.00 $896.50 $19,581.30 
Episode Duration (days) 29.88 54.39 1.00 1.00 1.00 38.00 359.00 
Median Age (years) 38.07 13.03 18 27 38 48 64 
CCI  0.21 0.53 0 0 0 0 8 
Behavioral Disorders 0.23 0.57 0 0 0 0 5 
 
Table 4.6 lists the frequencies of all encounters, psychotherapy encounters, medication 
management encounters, and the number of episodes. As expected, the proportion of episodes decreases 
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as the number of each type of encounter increases. Nearly 75% of the episodes of treatment do not 
involve psychotherapy and about two-thirds of episodes do not involve an SRI. In addition, about 43% of 
enrollees have more than one qualified episode. It was possible that other encounters were not included in 
the sample due to not meeting inclusion criteria determined a priori. This is also supported by the fact 
that nearly half of episodes included in the sample were preceded by at least one OCD-related encounter. 
 
Table 4.6. Frequencies and proportion by type of encounter. Total n =26,043 encounters.  
 Therapy Encounters Medication Mgmt. All Encounters Episodes 
Count n % n % n % n % 
0 19,153 73.54 17,166 65.91     
1 2,094 8.04 6,581 25.27 15,533 59.64 14,666 56.31 
2 1,025 3.94 1,327 5.10 3,416 13.12 5,880 22.58 
3 761 2.92 500 1.92 1,791 6.88 2,668 10.24 
4 587 2.25 238 0.91 1,130 4.34 1,389 5.33 
5 441 1.69 103 0.40 765 2.94 764 2.93 
6 407 1.56 51 0.20 588 2.26 375 1.44 
7 369 1.42 32 0.12 439 1.69 172 0.66 
8 383 1.47 18 0.07 372 1.43 89 0.34 
9 285 1.09 12 0.05 269 1.03 29 0.11 
10 55 0.21 2 0.01 280 1.08 9 0.03 
>10 483 1.85 13 0.05 1,460  5.61 2 0.01 
 
Table 4.7 provides the frequencies and proportions of categorical covariates used in this analysis. 
The episodes represent slightly more women (54% vs 46%), and over half of the enrollees are also the 
employee (or retiree). Most of the episodes are associated with PPOs, POS, and HMOs. Most enrollees 
represented in the episodes (90%) live in urban/suburban areas rather than rural areas. More than a third 
of the episodes occur in the Midwest region of the U.S., which may have implications for standards of 
care. Table 4.8 displays the frequencies of comorbid disorders taken from all other claims. The 
frequencies drop off precipitously as the number of disorders increase.  
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Table 4.7. Frequencies and proportions of categorical variables. Total n =26,043 encounters. 
Variable  N % 
Men 11,982 46.01 
Women 14,061 53.99 
Year   
2008 6,233 23.93 
2009 10,738 41.23 
2010 9,072 34.83 
Relation to Employee   
Employee 13,713 52.66 
Spouse 7,127 27.37 
Dependent 5,203 19.98 
Employment Status   
Current Employee 22,487 86.35 
Retiree 2,618 10.05 
Survivor  85 0.33 
Disabled 125 0.48 
COBRA 412 1.58 
Type of Insurance   
PPO 16,496 63.34 
POS 3,327 12.78 
HMO 3,317 12.74 
CDHP 1,093 4.20 
Comprehensive 904 3.47 
HDHP 427 1.64 
EPO 349 1.34 
POS Capitated 130 0.50 
Region   
Northeast 5,244 20.14 
North Central 7,191 27.61 
South 9,379 36.01 
West 4,229 16.24 
Urban/Rural   
MSA 23,496 90.22 
Rural 2,547 9.78 
Providers Seen   
Psychiatry 13,683 52.54 
Psychology 3,172 12.18 
Specialist 16,290 62.55 
General Practitioner  6,047 23.22 
SRI used   
Sertraline 4,231 16.25 
Paroxetine 1,571 6.03 
Fluoxetine 3,976 15.27 
Fluvoxamine 2,265 8.70 
Escitalopram 2,531 9.72 
Citalopram 1,757 6.75 
Clomipramine 1,133 4.35 
Previous OCD encounters 12,650 48.57 
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Table 4.8. Frequencies and percentages of comorbidities. Total n =26,043 encounters. 
 Charlson Comorbidity Index Behavioral Disorders 
Count N % N % 
0 21,788 83.66 21,668 83.20 
1 3,447 13.24 3,160 12.13 
2 618 2.37 931 3.57 
3 131 0.50 233 0.89 
4 40 0.15 41 0.16 
5 12 0.05 10 0.04 
6 4 0.02   
7 1 0.00   
8 2 0.01   
 
The histogram exploring the timing of the index encounter of the episode (Figure 4.7) displays a 
seasonal pattern, with more episodes initiating during the earlier part of the year and a decline as the year 
progresses. This is likely the effect of “resets” of annual plan benefits (e.g. deductibles, out-of-pocket 
maximums, allowed encounters). At the time the study claims were collected, it was common for insurers 
to limit the number of behavioral health encounters in a year, which may partly explain this trend. To 
account for this seasonality, variables for episode year, and initiation month were interacted and included 
in the regression analysis. 
Psychotherapy Intensity and Dose 
The primary analyses in Tables 4.9-4.10 examine the relationship between cost-sharing and 
utilization, controlling for covariates. In terms of model stability, all AME estimates are stable across 
models estimating psychotherapy intensity and dose without any changes in sign or relative magnitude. 
The association between cost-sharing, as a percent of total costs, and psychotherapy encounters during an 
episode are estimated to be -0.006 (SE: 0.001) and statistically significant (p <0.001, Table 4.9: Model 7). 
This represents a .006 fewer encounters for each 1 percentage point increase in cost-share. The practical 
interpretation of this is an enrollee under 100% cost-sharing would have 0.6 fewer psychotherapy 
encounters, on average, relative to an enrollee with no cost-sharing. With respect to psychotherapy dose, a 
1 percentage point increase in cost-sharing is associated with 0.30 (SE: 0.04) fewer minutes (p <0.001). 
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The impact for an enrollee subject to 100% cost-sharing is 30 fewer minutes of psychotherapy, on 
average, relative to enrollees without cost-sharing.  
 
Figure 4.7.  Histogram showing the timing of index encounters during the study period. Note the 
seasonality and spikes at the beginning of the year when plan benefits reset. 
 
The type of insurance plan does not have a statistically significant impact on the intensity of 
psychotherapy visits in the full model; however, enrollees with POS-capitated insurance have 32 more 
minutes of therapy (p <0.01), on average, relative to enrollees with comprehensive insurance (see Table 
4.10, Model 7). This difference remains robust when controlling for covariates. There are no other 
statistically significant differences by insurance plans.  
Year and month of episode initiation are both statistically significant covariates in the final 
models for psychotherapy intensity and dose (all p <0.001). In terms of year of initiation, episodes 
beginning in 2009 have 0.26 (SE: 0.05) more encounters and 13.70 (SE: 2.60) fewer minutes of 
psychotherapy dose, on average, relative to episodes initiated in 2008; however, episodes initiated in 2010 
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have 0.48 (SE: 0.05) fewer encounters and 23.62 (SE: 2.32) fewer minutes of psychotherapy. There 
appears to be a decreasing number of encounters as the year progressed (see Figure 4.7 and Tables 4.9-
10). For example, relative to January, there are 1.05 (SE: 0.12) fewer encounters initiated in February, 
1.62 (SE: 0.11) fewer encounters initiated in June, and 2.58 (SE: 0.10) fewer encounters initiated in 
December. A similar trend is observed for decreasing psychotherapy dose, relative to January, with 54.23 
(SE: 6.18) fewer minutes in February, 82.60 (SE: 5.76) fewer minutes in June, and 130.17 (SE: 5.07) 
fewer minutes in December. This pattern suggests, in accordance with some,17,110 but contrary to 
others,41,48 that the probability of initiating of care decreases over the course of the year.  
 Use of any SRI during the treatment episode is associated with a statistically significant (p 
<0.001) decrease of 0.37 psychotherapy encounters relative to enrollees who did not have any SRI 
prescriptions filled. However, the use of SRIs does not have a significant impact on the dose of 
psychotherapy.  
There is no significant variation by number of somatic comorbidities; however, increasing 
number of psychiatric comorbidity is statistically significantly associated with increased psychotherapy 
intensity and dose. For example, relative to enrollees with no additional psychiatric comorbidities, 
enrollees with 1, 2, and 3 psychiatric comorbidities have 0.17, 0.34, and 0.76 more psychotherapy 
encounters, respectively (all p <0.01). In terms of psychotherapy dose, a similar relationship is observed, 
with 9, 16, or 40 minutes more psychotherapy for those with 1, 2, 3 psychiatric comorbidities, 
respectively. There is no a statistically significant difference in terms of psychotherapy intensity or dose 
for enrollee with 4 or more psychiatric comorbidities.  
Enrollee age is statistically significantly associated with decreasing psychotherapy encounters (p 
<0.001), but not for psychotherapy dose. The AME estimates suggest that for each 1-year increase in age 
(centered at mean, 38 years), the number of psychotherapy encounters decreases by 0.008 (SE: 0.001). 
For instance, an 18-year-old enrollee would have 0.16 more psychotherapy encounters, on average 
compared to a 38-year-old, while a 64-year-old would have 0.21 fewer psychotherapy encounters. 
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There is no statistically significant relationship between sex and psychotherapy intensity or dose. 
The Midwest, South, and West have significantly lower psychotherapy intensity and dose, relative to the 
Northeast. Enrollees in the Midwest, South, and West have 0.58 (SE:0.05; p <0.001), 0.69 (SE: 0.05; p 
<0.001), and .23 (SE:0.06; p <0.001) fewer psychotherapy encounters, respectively, compared to 
enrollees in the Northeast. A similar pattern is found for psychotherapy dose whereby enrollees in the 
Midwest have 17.63 (SE: 1.97; p <0.001) fewer minutes, in the South have 18.41 (SE:1.89; p <0.001) 
fewer minutes, and in the West have 6.51 (SE:2.30; p <0.01) fewer minutes relative to enrollees in the 
Northeast.  
SRI Medication Adherence 
Logistic regression-based AME estimates of SRI adherence are found in Table 4.11 and show 
unstable estimates regardless of covariates included. The model estimates fail to support a relationship 
between cost-sharing and SRI adherence, but interpretation of results is cautioned due to model 
performance. The findings do not vary based on the threshold (MPRm) considered to be adherent as 
shown in the sensitivity analysis shown in Appendix Table 4.4.  
In terms of insurance plans, the probability of being adherent to SRIs (MRPm ≥0.80) was 5.9 
(SE: 2.7) percentage points lower for enrollees in HMO plants relative to enrollees in comprehensive 
plans (p <0.05). No other AME estimates for insurance plan were statistically significantly different than 
zero. In addition, the only other significant predictor of SRI adherence was utilization of psychotherapy 
during the episode of treatment. The AME estimates suggest that the probability of adherence for 
enrollees who had at least one psychotherapy encounter was 8.0 (SE: 1.0) percentage points lower relative 
to enrollees without psychotherapy (p <0.001). The remainder of the covariate estimates were not 
statistically different than zero. 
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Table 4.9: Average marginal effects estimates of psychotherapy visit intensity based on zero-inflated negative binomial regression estimates. 
Estimates represent the change in number of encounters for each percentage point increase in cost-share. Total n= 26,043 encounters, of which 
6,890 have at least one psychotherapy encounter.  
Estimate (SE) Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Cost-share -0.006 (0.001)‡  -0.006 (0.001)‡  -0.006 (0.001)‡  -0.007 (0.001)‡  -0.007 (0.001)‡  -0.007 (0.001)‡  -0.006 (0.001)‡  
Plan type         
Comprehensive  base base base base base base 
EPO  -0.255 (0.174) -0.170 (0.170) -0.149 (0.170) -0.154 (0.171) -0.186 (0.172) -0.203 (0.175) 
HMO  -0.177 (0.124) -0.153 (0.116) -0.130 (0.112) -0.137 (0.112) -0.173 (0.115) -0.188 (0.114) 
POS-FFS  0.189 (0.132) 0.173 (0.121) 0.186 (0.116) 0.177 (0.116) 0.145 (0.119) 0.083 (0.118) 
POS-Cap  0.676 (0.368) 0.800 (0.342)* 0.675 (0.325)* 0.674 (0.328)* 0.627 (0.327) 0.252 (0.272) 
PPO  0.032 (0.117) 0.001 (0.108) 0.020 (0.103) 0.015 (0.104) -0.011 (0.107) -0.019 (0.107) 
CDHP  -0.098 (0.148) -0.041 (0.140) -0.050 (0.135) -0.055 (0.135) -0.080 (0.138) -0.073 (0.139) 
HDHP  0.408 (0.315) 0.442 (0.248) 0.480 (0.250) 0.470 (0.249) 0.456 (0.254) 0.320 (0.229) 
Year         
2008   base base base base base 
2009   0.294 (0.055)‡  0.296 (0.054)‡  0.290 (0.054)‡  0.294 (0.054)‡  0.260 (0.054)‡  
2010   -0.488 (0.047)‡  -0.484 (0.047)‡  -0.491 (0.047)‡  -0.487 (0.047)‡  -0.483 (0.047)‡  
Month         
Jan   base base base base base 
Feb   -1.174 (0.129)‡  -1.163 (0.131)‡  -1.166 (0.131)‡  -1.183 (0.132)‡  -1.052 (0.124)‡  
Mar   -1.425 (0.123)‡  -1.429 (0.124)‡  -1.427 (0.124)‡  -1.440 (0.125)‡  -1.289 (0.118)‡  
Apr   -1.721 (0.117)‡  -1.728 (0.118)‡  -1.724 (0.118)‡  -1.727 (0.119)‡  -1.575 (0.113)‡  
May   -1.787 (0.117)‡  -1.797 (0.117)‡  -1.797 (0.117)‡  -1.797 (0.118)‡  -1.649 (0.111)‡  
June   -1.778 (0.116)‡  -1.775 (0.118)‡  -1.777 (0.118)‡  -1.789 (0.118)‡  -1.616 (0.112)‡  
July   -1.966 (0.114)‡  -1.982 (0.115)‡  -1.983 (0.115)‡  -1.989 (0.115)‡  -1.818 (0.109)‡  
Aug   -2.208 (0.111)‡  -2.228 (0.112)‡  -2.228 (0.112)‡  -2.233 (0.113)‡  -2.066 (0.105)‡  
Sept   -2.295 (0.110)‡  -2.230 (0.112)‡  -2.301 (0.112)‡  -2.299 (0.113)‡  -2.144 (0.105)‡  
Oct   -2.340 (0.112)‡  -2.359 (0.113)‡  -2.359 (0.113)‡  -2.355 (0.114)‡  -2.187 (0.107)‡  
Nov   -2.510 (0.111)‡  -2.533 (0.111)‡  -2.533 (0.111)‡  -2.254 (0.112)‡  -2.375 (0.104)‡  
Dec   -2.729 (0.106)‡  -2.748 (0.107)‡  -2.748 (0.107)‡  -2.750 (0.108)‡  -2.582 (0.100)‡  
SRI used     -0.381 (0.042)‡  -0.387 (0.042)‡  -0.413 (0.44)‡  -0.368 (0.043)‡  
CCI     -0.022 (0.033) 0.015 (0.034) 0.025 (0.035) 
Psych. Comorbidities         
0     base base base 
1     0.185 (0.059)♦  0.173 (0.059)♦  0.172 (0.058)♦  
2     0.405 (0.106)‡  0.389 (0.105)‡  0.344 (0.099)♦  
3     0.827 (0.271)♦  0.766 (0.258)♦  0.763 (0.260)♦  
4     1.007 (0.630) 0.850 (0.574) 0.781 (0.541) 
5     0.434 (0.873) 0.383 (0.841) 0.492 (0.938) 
Age      -0.008 (0.001)‡  -0.008 (0.001)‡  
Female      0.030 (0.036) 0.057 (0.035) 
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Table 4.9 continued: Average marginal effects estimates of psychotherapy visit intensity based on zero-inflated negative binomial regression 
estimates. Estimates represent the change in number of encounters for each percentage point increase in cost-share. Total n= 26,043, of which 
6,890 have at least one psychotherapy encounter.  
 Estimate (SE)  Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Region         
Northeast       base 
Midwest       -0.578 (0.053)‡  
South       -0.691 (0.052)‡  
West       -0.232 (0.063)‡  
‡: p <.001 ♦: p <.01 *: p <.05  SE: standard error EPO: exclusive provider organization HMO: health maintenance 
organization POS-FFS: point of service – fee-for-service POS-Cap: point of service capitated PPO: preferred provider organization
 CDHP: consumer-directed high-deductible HDHP: high-deductible health plan 
 
 
Table 4.10: Average marginal effects estimates of psychotherapy dose (in minutes) based on zero-inflated negative binomial regression estimates. 
Estimates represent the change in number of minutes of psychotherapy for each percentage point increase in cost-share. Total n= 26,043, of which 
6,890 have at least one psychotherapy encounter. 
Estimate (SE) Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Cost-share -0.273 (0.044)‡  -0.297 (0.044)‡  -0.320 (0.039)‡  -0.320 (0.039)‡  -0.320 (0.039)‡  -0.321 (0.039)‡  -0.302 (0.038)‡  
Plan type        
Comprehensive  base base base base base base 
EPO  -12.362 (9.011) -8.942 (8.846) -8.885 (8.835) -9.102 (8.877) -9.288 (8.289) -9.712 (8.781) 
HMO  -9.354 (6.274) -8.660 (5.888) -8.621 (5.870) -8.949 (5.898) -8.957 (5.898) -9.480 (5.751) 
POS-FFS  9.413 (6.697) 7.872 (6.127) 7.885 (6.110) 7.492 (6.130) 7.571 (6.135) 5.162 (5.963) 
POS-Cap  49.043 (19.815)* 44.484 (16.923)♦  44.294 (16.886)♦  44.322 (16.989)♦  43.750 (16.901)* 31.879 (15.022)* 
PPO  1.647 (5.935) -0.294 (5.520) -0.262 (5.502) -0.502 (5.533) -0.566 (5.537) -1.046 (5.409) 
CDHP  -4.714 (7.540) -2.495 (7.095) -2.522 (7.078) -2.806 (7.103) -2.692 (7.120) -2.541 (6.988) 
HDHP  21.146 (15.762) 19.500 (12.227) 19.542 (12.214) 19.111 (12.203) 18.706 (12.114) 14.075 (11.084) 
Year        
2008   base base base base base 
2009   15.339 (2.673)‡  15.343 (2.670)‡  15.113 (2.667)‡  15.167 (2.667)‡  13.703 (2.601)‡  
2010   -23.741 (2.335)‡  -23.708 (2.333)‡  -23.927 (2.345)‡  -23.906 (2.344)‡  -23.616 (2.318)‡  
Month        
Jan   base base base base base 
Feb   -58.921 (6.6521)‡  -58.855 (6.522)‡  -58.867 (6.511)‡  -58.802 (6.519)‡  -54.231 (6.180)‡  
Mar   -70.605 (6.296)‡  -70.556 (6.295)‡  -70.415 (6.287)‡  -70.591 (6.284)‡  -65.430 (5.983)‡  
Apr   -85.675 (5.912)‡  -85.618 (5.889)‡  -85.419 (5.912)‡  -85.519 (5.915)‡  -80.013 (5.622)‡  
May   -89.335 (5.888)‡  -89.286 (5.889)‡  -89.169 (5.882)‡  -89.219 (5.884)‡  -83.686 (5.575)‡  
   
 
87 
 
Table 4.10 continued: Average marginal effects estimates of psychotherapy dose (in minutes) based on zero-inflated negative binomial regression 
estimates. Estimates represent the change in number of minutes of psychotherapy for each percentage point increase in cost-share. Total n= 
26,043, of which 6,890 have at least one psychotherapy encounter. 
Estimate (SE) Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
June   -88.689 (5.860)‡  -88.610 (5.862)‡  -88.587 (5.847)‡  -88.689 (5.849)‡  -82.591 (5.575)‡  
July   -98.600 (5.777)‡  -98.552 (5.776)‡  -98.442 (5.751)‡  -98.536 (5.750)‡  -92.408 (5.448)‡  
Aug   -110.486 (5.608)‡  -110.436 (5.608)‡  -110.299 (5.602)‡  -110.313 (5.607)‡  -104.043 (5.306)‡  
Sept   -114.504 (5.614)‡  -114.420 (5.618)‡  -114.395 (5.611)‡  -114.488 (5.615)‡  -108.685 (5.310)‡  
Oct   -116.859 (5.711)‡  -116.804 (5.712)‡  -116.683 (5.705)‡  -116.799 (5.710)‡  -110.558 (5.396)‡  
Nov   -125.126 (5.631)‡  -125.080 (5.630)‡  -124.943 (5.624)‡  -125.028 (5.628)‡  -118.952 (5.300)‡  
Dec   -136.847 (5.375)‡  -136.778 (5.378)‡  -136.638 (5.370)‡  -136.724 (5.377)‡  -130.166 (5.069)‡  
SRI used     -0.668 (1.339) -0.743 (1.346) -0.657 (1.347)‡  -0.641 (1.296)‡  
CCI     -1.206 (1.241) -1.025 (1.270)‡  -0.649 (1.263)‡  
Psych. Comorbidities        
0     base base base 
1     9.172 (3.001)♦  9.230 (3.008)♦  9.139 (2.940)♦  
2     17.442 (5.204)♦  17.399 (5.197)♦  15.850 (4.920)♦  
3     40.550 (14.099)♦  40.355 (14.022)♦  39.466 (13.578)♦  
4     44.340 (29.274) 43.038 (29.090) 40.008 (27.025) 
5     18.714 (41.698) 19.121 (42.029) 22.435 (44.283) 
Median Age      -0.199 (0.054) -0.034 (0.052) 
Female      -2.213 (1.379) -1.456 (1.324) 
Region        
Northeast       base 
Midwest       -17.628 (1.969)‡  
South       -18.407 (1.893)‡  
West       -6.509 (2.296)♦  
‡: p <.001 ♦: p <.01 *: p <.05  SE: standard error EPO: exclusive provider organization HMO: health maintenance 
organization POS-FFS: point of service – fee-for-service POS-Cap: point of service capitated PPO: preferred provider organization
 CDHP: consumer-directed high-deductible HDHP: high-deductible health plan
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Table 4.11: Average marginal effects estimates of SRI medication possession ratio-modified based on logistic regression estimates. Estimates 
represent the change in probability of being adherent (MPRm ≥0.80) for each percentage point increase in cost-share. N = 16,205 with at least one 
SRI medication claim.  
Estimate (SE) Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Cost-share 0.0002 (0.0002) 0.0001 (0.0002) 0.0001 (0.0002) 0.0001(0.0002) 0.0000 (0.0002) 0.0000 (0.0002) 0.0000 (0.0002) 
Plan type        
Comprehensive  base base base base base base 
EPO  -0.013 (0.042) -0.014 (0.043) -0.010 (0.042) -0.009 (0.043) -0.008 (0.043) -0.008 (0.043) 
HMO  -0.060 (0.027)* -0.058 (0.027)* -0.060 (0.027) -0.059 (0.027)* -0.059 (0.027)* -0.059 (0.027)* 
POS-FFS  -0.024 (0.027) -0.022 (0.027) -0.022 (0.027) -0.022 (0.027) -0.021 (0.027) -0.019 (0.027) 
POS-Cap  0.025 (0.064) 0.026  (0.064) 0.027 (0.064) 0.026 (0.064) 0.027 (0.064) 0.034 (0.063) 
PPO  -0.032 (0.024) -0.030 (0.024) -0.030 (0.024) -0.030 (0.024) -0.030 (0.024) -0.030 (0.024) 
CDHP  -0.027 (0.032) -0.031 (0.032) -0.033 (0.032) -0.033 (0.032) -0.032 (0.032) -0.032 (0.032) 
HDHP  0.010 (0.039) 0.013 (0.039) 0.0136 (0.039) 0.014 (0.039) 0.015 (0.039) 0.012 (0.039) 
Any Psychotherapy   -0.088 (0.010)‡ -0.081 (0.010)‡ -0.080 (0.010)‡ -0.080 (0.010)‡ -0.080 (0.010)‡ 
Year        
2008    base base base base 
2009    -0.000 (0.011) 0.001 (0.011) 0.001 (0.011) 0.002 (0.011) 
2010    -0.001 (0.012)  0.001 (0.012) 0.001 (0.012) 0.002 (0.012) 
Month        
Jan    base base base base 
Feb    0.026 (0.017) 0.026 (0.017) 0.026 (0.017) 0.026 (0.017) 
Mar    -0.011 (0.017) -0.011 (0.017) -0.011 (0.017) -0.011 (0.017) 
Apr    -0.014 (0.017) -0.014 (0.017) -0.014 (0.017) -0.013 (0.017) 
May    -0.012 (0.017) -0.012 (0.017) -0.012 (0.017) -0.012 (0.017) 
June    -0.006 (0.017) -0.005 (0.017) -0.005 (0.017) -0.005 (0.017) 
July    0.004 (0.017) 0.005 (0.017) 0.005 (0.017) 0.005 (0.017) 
Aug    -0.001 (0.017) -0.001 (0.017) -0.001 (0.017) -0.001 (0.017) 
Sept    0.018 (0.018) 0.018 (0.018) 0.018 (0.018) 0.018 (0.018) 
Oct    0.014 (0.021) 0.014 (0.207) 0.014 (0.021) 0.014 (0.021) 
Nov    0.067 (0.023)♦ 0.068 (0.023)♦ 0.068 (0.023)♦ 0.068 (0.023)♦ 
Dec    0.190 (0.025)‡ 0.190 (0.025)‡ 0.191 (0.025)‡ 0.190 (0.025)‡ 
CCI     -0.004 (0.008) -0.005 (0.009) -0.005 (0.009) 
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Table 4.11 continued: Average marginal effects estimates of SRI medication possession ratio-modified based on logistic regression estimates. 
Estimates represent the change in probability of being adherent (MPRm ≥0.80) for each percentage point increase in cost-share. N = 16,205 with at 
least one SRI medication claim.  
Estimate (SE) Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Psych. 
Comorbidities 
       
0     base base base 
1     -0.019 (0.013) -0.020 (0.013) -0.020 (0.013) 
2     -0.004 (0.022) -0.004 (0.022) -0.004 (0.022) 
3     -0.012 (0.044) -0.012 (0.044) -0.013 (0.044) 
4     -0.161 (0.098) -0.160 (0.098) -0.163 (0.097) 
5     -0.196 (0.192) -0.195 (0.193) -0.196 (0.195) 
Median Age      0.000 (0.000) 0.000 (0.000) 
Female      0.006 (0.009) 0.006 (0.009) 
Region        
Northeast       base 
Midwest       0.016 (0.013) 
South       0.002 (0.012) 
West       0.027 (0.015) 
Notes: ‡: p <.001 ♦: p <.01 *: p <.05   
SE: standard error EPO: exclusive provider organization HMO: health maintenance organization  POS-FFS: point of 
service – fee-for-service POS-Cap: point of service capitated PPO: preferred provider organization CDHP: consumer-directed high-
deductible HDHP: high-deductible health plan 
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Discussion 
 Optimization of behavioral health service use requires finding the balance between deterring low-
value care and encouraging high-value, EBPs. Insurers, as the primary payers for many individuals, have 
a vested interest in efficient allocation of limited resources related to care. This interest has led to 
different insurance plan designs ranging from managed care based (HMOs and EPOs) to fee-for-service 
based (PPO and POS) and to newer high-deductible plans (CDHP and HDHP). All of  these insurance 
benefit designs use unique combinations of utilization management and cost-sharing to guide patients and 
providers toward high-value care. As more individuals gain insurance under these types of plans 
(including through Medicaid managed care and Medicare Advantage plans), more research is needed to 
understand how benefit designs influence patient behavior, especially across diagnostic classes and 
services.  
Intensity and dose of psychotherapy is sensitive to patient cost-sharing for adults with OCD under 
commercial insurance plans. The estimated association between cost-sharing and outpatient 
psychotherapy use is not directly comparable to previous work estimating price elasticity of demand or 
arc elasticities of demand due to differences in dependent variables and methodology. For example, work 
based on the Rand HIE uses an experimental design that varied benefit levels,6,8,14,113,114 while other work 
has compared pre-post differences in utilization after a change in policy benefits.20,22,99,102,115,116 Despite 
these difference, the vector of the estimates obtained here (AME for encounters: -0.006), aligns with 
previous work, although they are nearly an order of magnitude smaller than would be expected 
(approximately -0.06 to -0.20).8,19,20,117 This might be due to the differences in dependent variable, since 
this study limited demand to psychotherapy encounters, rather than all behavioral health service 
encounters, or all outpatient encounters generally. Nonetheless, cost-sharing is negatively associated with 
receipt of psychotherapy. To augment these findings, cost-sharing was regressed on dose of 
psychotherapy. These results suggest that cost-sharing also has a weak, but significant association with 
total dose of psychotherapy received. Taken together, insurers and providers should be aware of this 
financial barrier to achieving the 1500 minutes, or 13-20 encounters, of recommended psychotherapy.58  
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 The lack of differences by insurance plan type was likely due to heterogeneity within plan 
categories since plans were aggregated without information about specific plan benefit design. Of note, 
the sole capitated plan (POS-Cap) showed roughly a one psychotherapy encounter increase over the 
comprehensive plan. This might be due to the value-based insurance design, whereby the providers are 
provided a flat fee per diagnostic group, with adjustments to quality and outcomes.105,118 If true, this 
would support the case for value-based behavioral health insurance. In addition, others have noted that the 
nonlinearity of insurance benefit design complicates analyses,8 which may also play a role in the 
nonsignificant findings since plans were summarized using a single cost-sharing variable.  
There was strong evidence of seasonality with respect to episode initiation. Episodes were more 
likely to be initiated at the beginning of the year. This may be due to the benefit “reset” that occurs at the 
beginning of the plan year, which is typically January first. If due to the reset, this would suggest that 
patients delay care necessary care throughout the year. It also has implication for plan limits on the 
number of psychotherapy encounters. The year of episode initiation is also related to psychotherapy 
intensity and dose. Interestingly, demand was significantly higher in 2009, but lower in 2010, relative to 
2008. One plausible explanation is the use of services in 2009 in response to stress related to the financial 
recession that began in 2008, but as the financial outlook remained uncertain in 2010, patients delayed 
care for non-emergent conditions.119 As others have found,15,22 utilization of outpatient mental health 
services were lower for the Midwest, South, West relative to the Northeast. This phenomenon might be 
due to the concentration of people, providers, and academic institutions in the Northeast. 
 Enrollees with more comorbid behavioral, but not comorbid somatic, disorders were significantly 
more likely to have higher intensity of psychotherapy encounters. The association of psychiatric 
comorbidity and psychotherapy intensity and dose was of the largest magnitude of any covariate, 
resulting in nearly one additional encounter. This makes intuitive sense as more comorbid psychiatric 
disorders often indicates higher acuity patients, whom would likely gain more benefit from care seeking. 
Somewhat paradoxically, enrollees with 4 or more comorbid disorders were not significantly more likely 
to utilize care, relative to those with none. This is mostly an artifact of instability in estimators due to a 
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small number of enrollees in this subpopulation (n =50). Use of any SRI during the episode resulted in 
lower intensity of psychotherapy, but no significant difference in dose. It is possible that these patients 
discontinued psychotherapy prematurely upon symptom remission due to SRIs.  
SRI adherence was not associated with cost-sharing in this model; however, given the lack of 
virtually any significant estimators, caution should be used when interpreting these findings. Literature 
reviews have found that 85% of articles reviewed demonstrated a statistically significant relationship 
between cost-sharing and medication adherence.69 In light of previous price elasticity of demand 
estimates ranging from -0.6 to -0.1,42,68 it was surprising that no relationship emerged. Potential problems 
with the model include model misspecification, lack of variation in the dependent variable, or lack of data 
detail such as household income or patient education level.  
Limitations 
This analysis utilized an insurance claims database, which presents some limitations. First, only 
limited demographic variables were available (i.e., age, sex, MSA) precluding analysis on 
sociodemographic variables such as income, education, and race/ethnicity. Previous studies were able to 
control for these factors directly, or indirectly through linking census data to zip code or similar 
geography. The dataset, as provided, did not include geographic information below the MSA-level. This 
limits the generalizability of the findings. Second, plan-specific information was not available; therefore, 
information on deductible, maximum out-of-pocket, and plan coverage was not available. However, the 
database did contain all post-adjudicated claims lines, for which there was detailed information about 
actual amounts paid towards deductible, coinsurance, and copayment. These amounts are empirically 
derived rather than approximated, which may improve their usefulness and the generalizability of the 
findings. It was also possible to make informed assumptions about limits such as deductible in cases 
where the sum of payments toward deductible ceased at an integer (e.g., $100, $250, $500) despite 
continued encounters. Third, like most claims analysis, there was no information on the premiums paid by 
the enrollee, family, or employer. Premium payments were assumed to be a sunk cost and have negligible 
impact on future service utilization. In addition, the employer likely paid a substantial portion, if not all 
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the premium, minimizing the expense to the enrollee. The exception to this would be enrollees covered 
under a COBRA plan.  
The database utilized in this study, may not be fully representative of insurance plans available 
today. In the intervening years since the study period, several important pieces of legislation have had a 
direct effect on cost-sharing and coverage of behavioral health services. For example, the MHPAEA was 
passed in 2008 and took effect July 1, 2010. This act required that if employer-based insurers opted to 
cover behavioral health services, the benefits had to be least as generous as medical services, such that the 
cost-sharing, coverage limits, and utilization management methods were equitable. The PPACA of 2010 
expanded this requirement to the individual market employers with 50 or more employees. It should be 
noted that 1) plans are still not required to cover behavioral health services; and 2) ERISA entities (i.e., 
large self-insured employers) may opt out of these requirements by filing annual notice with the federal 
government and enrollees. In the study database, all plans provided at least some behavioral health 
benefits, although the details of benefits are unknown. Finally, due to the observational nature of the 
dataset, there was no randomization into varying cost-sharing levels, so no causation can be inferred. 
Despite, these limitations, the dataset is useful for assessing the relationship between cost-sharing and 
psychotherapy and pharmacotherapy utilization in adults with OCD with health insurance coverage.  
 
Conclusion 
This study examined treatment of OCD among commercially insured adults, finding that cost-
sharing is significantly, negatively associated with psychotherapy intensity, measured as number of 
encounters, and psychotherapy dose, measured in minutes, for privately insured adult patients. This study 
found the association to be robust, regardless of other covariates. On the contrary, adherence to SRI 
medications, as measured by MPRm, was not associated with cost-sharing. These findings and have 
implications for patients, parents, clinicians, payers, and policymakers. The next iteration of insurance 
benefit design should use this information to deliver value-based products that encourage the use of EBPs 
through incentives.  
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CHAPTER 5: 
CONCLUSION 
 
 
 
Summary 
Approximately 20% of U.S. adults are living with a behavioral health disorder1 costing over $500 
billion in medical costs and lost wages annually.2,3 Furthermore, nearly a third of the population will 
experience a behavioral health disorder in their lifetime.4 Given the prevalence of disorders and the 
magnitude of the burden, behavioral health disorders are reasonable foci for using health services research 
methods to examine ways to reduce costs, enhance quality, and improve access relating to behavioral 
health services. The results of these research areas can support or be incorporated into evidence-based 
practices (EBPs). However, behavioral health services lag somatic health disorders, in terms of generating 
the requisite evidence for the design and implementation of EBPs. 
 In this dissertation, a variety of datasets and methods were used to answer three distinct research 
questions, in the interest of generating evidence for EBPs. Each chapter utilized a different dataset and 
methods to answer the question of interest, which was matched to the nature of the question and available 
data. Each of the dissertation chapters is briefly summarized below with discussions of applications to 
health policy and future research.  
 
 Chapter 2: Epidemiology of Disorders 
Chapter 2 focused on the research question, how do we optimize behavioral health screening 
among patients seen in the emergency department (ED)? The focus of this chapter is screening among 
patients treated in the ED for an injury, since injuries are relatively easy to observe. Using a large, 
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national hospital discharge dataset, the epidemiology of psychiatric disorders was assessed among adults 
seen in the ED for unintentional, intentional, and undetermined cause of injury. This chapter tested three 
hypotheses: 1) patients with injuries are more likely to have a diagnosed psychiatric disorder relative to 
patients without injuries; 2) patients with intentional injuries (self-harm or assault) are more strongly 
correlated with diagnosed psychiatric disorders relative to patients with unintentional injuries; and 3) 
patients with undetermined injuries are more likely to have a diagnosed psychiatric disorder relative to 
patients with unintentional injuries.  
The first analysis in Chapter 2 failed to find a significant difference in the likelihood of 
psychiatric disorders for patients seen in the ED for injuries relative to patients seen in the ED for all 
other reasons. This was contrary to previous work and did not support the first hypothesis. It was likely 
attributable to the decision to group individuals with primarily psychiatric symptoms with non-injury 
encounters. The second hypothesis could not be directly tested due to the presence of effect measure 
modification. Stratifying by disorder category allowed for analysis that showed that each psychiatric 
disorder tested was significantly more likely among patients with self-inflicted injuries relative to patients 
with unintentional injuries. However, patients seen in the ED for assault-related injuries were not more 
likely to have psychiatric disorders compared to patients seen for unintentional injuries. Therefore, the 
second hypothesis was partially supported. The third analysis showed that the probability of having 
anxiety, depression, and psychoses was higher among patients with injuries of undetermined cause 
relative to patients with unintentional injuries. These findings partially support the third hypothesis since 
the association was not robust for all psychiatric disorders.  
Overall, the results of Chapter 2 suggest that screening for psychiatric disorders guided by cause 
of injury is feasible. The lack of robust associations across disorder types is useful in differentiating 
which disorder should be screened based on the cause of injury presentation. For example, among patients 
with underdetermined cause of injury, screening for depression, anxiety, and psychoses would be efficient 
given the relative risks (>1.5), but screening for manic mood or ‘other’ disorders would not (relative risks 
< 1.0). There is also robust evidence for screening patients with self-harm injuries for all psychiatric 
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disorder. Finally, it would reasonable to universally screen for depression in light of the prevalence. 
Indeed, this was recommended by the U.S. Preventative Services Task Force.5  
 
Chapter 3: Cost-Benefit Analysis 
 Chapter 3 ranked the first-line treatments of obsessive-compulsive disorder (OCD) among 
children and adolescents using a cost-benefit analysis (CBA). The current guidelines call for cognitive 
behavioral therapy (CBT) and/or antidepressant medication (ADM) pharmacotherapy.6 Clinical trials 
have shown both treatments to be effective as monotherapies or in combination.7-11 There is only one 
cost-effectiveness analysis of OCD treatments; however, the study centered around the United Kingdom’s 
health system, incorporated low-quality evidence, and made several assumptions based on adult trials. 
Considering these limitations, and the mixed evidence of superiority from randomized control trials, it is 
difficult to synthesize and interpret the empirical findings in the context of the U.S. healthcare system. 
Chapter 3 used previously published trials and Monte-Carlo simulations to directly compare the 
treatments in terms of costs and benefits to rank-order OCD treatments. It was hypothesized that CBT 
monotherapy would be the most cost-beneficial treatment.  
 The results revealed that CBT monotherapy, augmented with ADM therapy, was the most cost-
beneficial strategy and resulted in the largest decrease in symptom score. This was true despite CBT 
augmented with ADM therapy being costlier compared to ADM monotherapy. There is some support for 
the hypothesis that CBT is most cost-beneficial with the caveat that it be augmented with ADM. The 
results of the CBA agree with the U.K. cost-effectiveness study, which found that strategies incorporating 
CBT were most cost-effective.12  Based on these findings, the initial treatment for most children and 
adolescents with OCD should be CBT, which can be augmented with either ADM or CBT in cases of 
treatment resistance. These findings supported the current practice guidelines. The major contributions of 
this chapter are the use of meta-analytic frameworks to conduct cost analyses and the addition of the first 
U.S. CBA of first-line treatments for children and adolescents with OCD.  
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Chapter 4: Economic Analysis of Claims Data 
 Chapter 4 examined the associations between cost-sharing and psychotherapy intensity and 
dosage and between cost-sharing and medication adherence among adults diagnosed with OCD. Decades 
of previous research has shown that patients are responsive to the price of healthcare, using more when 
prices are low and less when prices are higher.13-16 Moreover, the current evidence indicates that 
behavioral health services might be more sensitive to price relative to somatic health, but the estimates of 
price sensitivity vary widely.17-22 The literature further suggests that sensitivity to price may be moderated 
by the type of services rendered. Therefore, Chapter 4 examined the association between cost-sharing and 
behavioral health service utilization, for the two first-line treatments recommended for OCD. It was 
hypothesized that cost-sharing is inversely associated with the intensity (number of encounters) and 
dosage (in minutes) of psychotherapy for privately insured adults with an OCD diagnosis. It was also 
hypothesized that cost-sharing is negatively associated with adherence to serotonin reuptake inhibitors 
(SRIs).  
 The results suggest that psychotherapy intensity and dose are significantly, but weakly sensitive 
to cost-sharing requirements, regardless of insurance plan design. This follows the direction of the 
relationship found in previous work. Yet the estimated effects were an order of magnitude smaller than 
expected. There are a few reasons why this might be true. First, the rate of initiation of psychotherapy 
appeared to lower than one would expect based on previous research of depression. Second, it is possible 
that homogeneity in the number of psychotherapy encounters masked any differences that may exist. 
Third, SRIs are an alternative to psychotherapy and the more prevalent treatment, which might account 
for the low uptake of psychotherapy.  
In contrast to previous research, adherence to SRI medications was not associated with cost-
sharing. It was expected that adherence would be lower among patients with higher average cost-sharing 
levels. The lack of findings is mostly due to problems with the estimation model for adherence since no 
other covariates were statistically significant predictors. The major contribution of this chapter is the 
estimate of the relationship between cost-sharing and OCD. Since this was one of the first studies of cost-
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sharing for disorder-specific treatment utilization and adherence in behavioral health, more work is 
needed to confirm the findings and assess other behavioral health disorders.  
 
Policy and Practice Implications 
 Chapter 2 
 The findings for each chapter in this dissertation has implications for health policy and practice. 
Chapter 2 showed that specific psychiatric disorders are more likely among each of the causes of injury.  
Since injuries are objectively easier to observe compared to psychiatric disorders, using psychiatric 
disorders to guiding screening may improve efficiency of screening in the ED. Other researchers and 
clinicians have called for improving screening of psychiatric disorders in the ED,23-25 but imposing 
universal screening is not ideal in already overburdened EDs. Considering the burden of screening, rapid 
assessment is ideal and can be partially accomplished through use of screening heuristics to decide whom 
to screen. This approach does not presume to capture every occurrence of a  psychiatric disorder. It is 
intended as a first step toward better identification of individuals with behavioral health disorders within 
existing healthcare systems. Further research and refinement is needed to better elucidate the relationships 
between injuries and psychiatric disorders and the best method(s) to screen patients. Patients who screen 
positive can be directed into appropriate inpatient or outpatient behavioral health services. In this way, 
screening patients improves access to care. In addition, a positive screen could trigger additional protocols 
and social supports that improve the quality of care received at the time of injury.  
 Chapter 3 
 Chapter 3 has implications across several aspects of health policy. For example, the results can be 
incorporated into the supporting evidence for the next iteration of EBPs for children and adolescents with 
OCD. The findings support high-value treatment strategies, which are currently the first-line treatment. In 
addition, clinicians, patients, and parents can immediately use the results to inform treatment choices 
given the totality of the patient’s circumstances and preferences. For example, patients facing financial or 
   
 
116 
 
geographic barriers can select the most pragmatic option from the non-dominated treatment strategies 
with the understanding that alternative may be less effective or more expensive. 
The results can also be used by policymakers and insurers to devise clinician reimbursement and 
health insurance benefits that encourage the use of the most cost-beneficial treatment strategies. For 
instance, UnitedHealth publicizes ratings of physicians based on the quality and efficiency of practice 
patterns.26 Patients insured with this carrier are incentivized to use these physicians through reduced 
copayments. The findings of Chapter 3 should not be considered absolute rankings of treatment 
effectiveness and should not be used as a rationale to deny care. Given the significant heterogeneity in 
patients, clinical judgement should play the leading role in treatment plans. Nevertheless, the results of 
Chapter 3 provide empirical evidence supporting high-quality, efficient treatment of OCD.  
 Chapter 4 
 The results of Chapter 4 can be used to inform future insurance plan design such that financial 
barriers to receiving EBPs are mitigated, while providing benefits for effective treatments. Previous 
research has examined moral hazard as it applies to overall healthcare utilization, somatic health services, 
behavioral health services, and most recently, to disorder-specific services. As the insurance market 
moves increasingly towards value-based insurance design, evidence is needed to design health insurance 
plans so that high-value care is maximized while minimizing low-value care. Even though Chapter 4 
utilized a privately-insured sample, the findings are applicable to Medicare and Medicaid, especially in 
cases where benefits are administered by managed care providers. In many cases Medicaid programs 
require a small copayment, but Medicare plans require copayments like those found in private insurance 
plans. Furthermore, the private insurance industry generally shifts plan benefits to mirror Medicare 
policies changes, which can be harnessed to speed the implementation of  value-based insurance design 
elements such as reduced cost-sharing for high-value care.  
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Future Research 
 There were some limitations to these studies presented in Chapters 2 through 4. With respect to 
the association between cause of injury and psychiatric disorders, more work is needed to determine the 
underlying prevalence of diagnosable psychiatric disorders by cause of injury. The present work is limited 
to psychiatric disorders that were diagnosed before discharge, and likely excludes a sizeable proportion of 
individuals with psychiatric disorders that were not diagnosed at all. Therefore, future experiments should 
screen patients for psychiatric illnesses using sensitive and specific instruments after being assessed by 
clinicians, but before discharge. This approach would have at least two benefits:  it would offer better 
prevalence estimates and would demonstrate the value and clinical utility of targeted screening to 
physicians.  
 Research examining the cost of treatments should begin with current EBPs, and when possible, 
the best available clinical evidence. In Chapter 3, the results were limited to previously collected data that 
did not collect information on patient quality of life, which made it impossible to conduct a rigorous cost-
effectiveness analysis. All future research investigating clinical effectiveness should capture quality of 
life estimates using vetted questionnaires. This would allow comparison of treatment costs and effects 
across all conditions and treatments that have existing quality of life and cost information.  
The analysis was limited to first-line treatments and augmentation strategies because these 
interventions are most common; however, there are patients who do not adequately respond to these 
treatments, requiring additional psychological, surgical, and pharmacological treatment strategies. These 
individuals represent a subpopulation that have significantly more acuity, requiring more invasive 
strategies. More information from control trials is needed to compare strategies beyond the first-line. The 
study was limited to the perspective of the payer, which excludes costs borne by patients, families, and 
society. These costs can be substantial, even eclipsing the actual cost of care. Future research should build 
on this work through conducting and disseminating cost analyses for other behavioral (and somatic) 
health disorders not yet reviewed. 
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Chapter 4 was subject to limitations common to claims-based research, such as limited 
demographic information, limited insurance benefit information, and limitations on generalizability 
beyond the sample population. Future research should be conducted using multiple methods to obtain 
detailed data on patients, clinicians, and insurance plans. For example, surveys collecting socioeconomic 
information would be helpful to ensure robust findings across race/ethnicity, household income, 
geographic location, and other relevant subpopulations. In addition, the lack of information regarding 
patient preference for treatment should be addressed since patient preferences are central part of EBPs 
and might help better explain patterns of utilization. Future research should seek to confirm these 
findings, and if robust, offer additional analyses based on the socioeconomic factors mentioned above. 
More research is needed to assess the relationship between cost-sharing and utilization of services specific 
to other behavioral health disorders.  
The analysis in Chapter 4 was limited to privately insured patients prior to the full 
implementation of two important pieces of healthcare legislation. Therefore, the results may not 
generalize beyond this population and timeframe. Additional work examining the relationship of cost-
sharing and behavioral health service use should incorporate subpopulations that were not included in this 
analysis. For example, these subpopulations should be examined children and adolescents, elderly, 
Medicare and Medicaid beneficiaries, and others. Finally, the analysis presented in Chapter 4 was limited 
by the relatively simplistic measure of cost-sharing that did not consider non-linear benefits, defined plan 
benefits, and temporal effects. Others have used spot price, shadow price, expected end of year price, and 
out-of-pocket costs. These methods may be more sensitive to changes or may better reflect reality to the 
detriment of ease of implementation. Clearly, there remains much to do in this domain. 
 
Conclusion 
This dissertation has provided evidence to support improvements in areas of cost, quality, and 
access to behavioral health services. The preceding chapters explored ways to improve each of these areas 
using variety of data sources and methods. Chapter 2 focused on the epidemiology of psychiatric 
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disorders among adult patients who are seen in the ED for injuries. Chapter 3 examined the cost-benefits 
of guideline-recommended treatment for children and adolescents with OCD. Chapter 4 assessed the 
relationship between cost-sharing and utilization of psychotherapy and SRI medications for adults with 
OCD.  
 There were several important findings that emerged. First, psychiatric disorders are relatively 
common among adults with intentional or unknown cause of injury. Second, screening efficiency can be 
optimized by targeting specific disorders based on the cause of injury. Knowing about comorbid 
psychiatric disorders may improve the quality of care in the ED and access to behavioral health services 
in the ED and outpatient departments. Third, guideline-concordant care for children and adolescents with 
OCD can be optimized by the combination of and order of administration of treatments. The ranking of 
treatments supports the most cost-effective, highest-quality services are provided, and further provides 
information about alternatives. Fourth, cost-sharing is negatively associated with psychotherapy visit 
intensity and dose, but not associated with adherence to SRI medications. This finding has important 
implications for insurance design, clinician prescribing, and patient preferences. In addition, it 
demonstrates the problems that high costs pose to access of quality care, even among those with private 
insurance.  
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APPENDIX 
 
 
Table A4.1. Zero-inflated negative binomial model estimates for psychotherapy intensity, comparing null 
model to full model. Model estimates are divided into the negative binomial (NB) equation that estimates 
the log count of encounters conditional on non-zero use, and the logit equation that estimates the log odds 
of any psychotherapy use. N= 26,043 encounters. SEs are adjusted for 17,161 family clusters. 
Estimate (SE) NULL MODEL FULL MODEL 
Wald X
2 
3.87 1310.91 
Pr > X
2 
0.0492 <0.001 
Nonzero Obs. 6,890 6,890 
Zero Obs. 19,153 19,153 
NB ESTIMATES    
Cost-Share (%) -0.002 (0.001)* -0.003 (0.001)‡ 
Plan Type   
Comprehensive  base 
EPO  -0.308 (0.192) 
HMO  -0.317 (0.102) 
POS-FFS  -0.078 (0.100)♦ 
POS-Cap  -0.000 (0.169) 
PPO  -0.099 (0.094) 
CDHP  -0.101 (0.121) 
HDHP  -0.078 (0.157) 
Year   
2008  base 
2009  0.250 (0.043)‡ 
2010  -0.531 (0.472)‡ 
Month   
Jan  base 
Feb  -0.264 (0.056)‡ 
Mar  -0.414 (0.060)‡ 
Apr  -0.616 (0.061)‡ 
May  -0.684 (0.059)‡ 
June  -0.605 (0.060)‡ 
July  -0.846 (0.066)‡ 
Aug  -1.110 (0.071)‡ 
Sept  -1.175 (0.081)‡ 
Oct  -1.361 (0.085)‡ 
Nov  -1.770 (0.106)‡ 
Dec  -2.857 (0.144)‡ 
RX used   -0.304 (0.035)‡ 
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Table A4.1 continued. 
Estimate (SE) NULL MODEL FULL MODEL 
NB ESTIMATES    
CCI  0.022 (0.030) 
Psych Comorbidities   
0  base 
1  0.072 (0.046) 
2  0.026 (0.070) 
3  0.084 (0.155) 
4  0.289 (0.270) 
5  0.449 (0.370) 
Median Age  -0.007 (0.001)‡ 
Female  0.049 (0.030) 
Region   
North East  base 
Midwest  -0.448 (0.041)‡ 
South  -0.565 (0.040)‡ 
West  -0.156 (0.043)‡ 
Intercept 0.939 (0.055)‡ 2.610 (0.116)‡ 
Alpha 2.684 (0.203)  
LOGIT ESTIMATES   
Cost-Share (%) 0.010 (0.004)* 0.007 (0.004)* 
Plan Type   
Comprehensive base base 
EPO 0.493 (0.527) 0.375 (0.474) 
HMO -0.371 (0.247) -0.441 (0.220)* 
POS-FFS -0.024 (0.247) -0.023 (0.214) 
POS-Cap 2.638 (1.285)* 1.774 (1.223) 
PPO 0.081 (0.211) 0.005 (0.185) 
CDHP 0.161 (0.272) 0.064 (0.238) 
HDHP -0.622 (0.455) -0.736 (0.404) 
Cost-share* EPO -0.018 (0.014) -0.019 (0.013) 
Cost-share*HMO 0.008 (0.006) 0.006 (0.005) 
Cost-share*POS-FFS -0.008 (0.005) -0.008 (0.004) 
Cost-share*POS-Cap -0.106 (0.044)* -0.073 (0.040) 
Cost-share*PPO -0.006 (0.004) -0.005 (0.004) 
Cost-share*CDHP -0.006 (0.005) -0.004 (0.005) 
Cost-share*HDHP -0.000 (0.007) 0.003 (0.006) 
Year   
2008 base base 
2009 -0.014 (0.057) 0.117 (0.058)* 
2010 0.276 (0.066)‡ -0.091 (0.069) 
Month   
Jan base base 
Feb 0.800 (0.131)‡ 0.435 (0.082)‡ 
Mar 0.914 (0.129)‡ 0.435 (0.082)‡ 
Apr 1.079 (0.128)‡ 0.463 (0.082)‡ 
May 1.111 (0.131)‡ 0.458 (0.083)‡ 
June 1.170 (0.131)‡ 0.544 (0.080)‡ 
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Table A4.1 continued. 
Estimate (SE) NULL MODEL FULL MODEL 
LOGIT ESTIMATES   
July 1.243 (0.132)‡ 0.465 (0.086)‡ 
Aug 1.499 (0.138)‡ 0.546 (0.096)‡ 
Sept 1.651 (0.142)‡ 0.641 (0.102)‡ 
Oct 1.544 (0.151)‡ 0.448 (0.116)‡ 
Nov 1.828 (0.164)‡  0.444 (0.149)* 
Dec 2.253 (0.165)‡ -0.143 (0.284) 
Psych Comorbidities   
0 base base 
1 -0.213 (0.075)♦ -0.132 (0.069) 
2 -0.633 (0.144)‡ -0.493 (0.126)‡ 
3 -1.305 (0.360)‡ -1.015 (0.294)♦ 
4 -0.887 (0.669) -0.486 (0.541) 
5 -0.519 (1.622) 0.154 (0.973) 
Intercept -1.370 (0.289)‡ -0.226 (0.199) 
Notes: ‡: p <.001 ♦: p <.01 *: p <.05   
SE: standard error  
EPO: exclusive provider organization  
HMO: health maintenance organization  
POS-FFS: point of service – fee-for-service  
POS-Cap: point of service capitated  
PPO: preferred provider organization  
CDHP: consumer-directed high-deductible  
HDHP: high-deductible health plan 
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Table A4.2. Zero-inflated negative binomial model estimates for psychotherapy dose, comparing null 
model to full model. Model estimates are divided into the negative binomial (NB) equation that estimates 
log count of  psychotherapy minutes conditional on non-zero use, and logit equation that estimates to 
model the log odds of at least one encounter. N= 26,689 encounters. SEs are adjusted for 17,161 family 
clusters.  
Estimate (SE) NULL MODEL FULL MODEL 
Wald X
2 
4.49 1673.93 
Pr > X
2 
0.0341 <0.001 
Nonzero Obs. 6,890 6,890 
Zero Obs. 19,153 19,153 
NB ESTIMATES    
Cost-Share (%) -0.001 (0.001)* -0.002 (0.000)‡ 
Plan Type   
Comprehensive  base 
EPO  -0.218 (0.125) 
HMO  -0.229 (0.073)♦ 
POS-FFS  -0.057 (0.073) 
POS-Cap  0.080 (0.121) 
PPO  -0.082 (0.069) 
CDHP  -0.054 (0.085) 
HDHP  -0.069 (0.115) 
Year   
2008  base 
2009  0.193 (0.028)‡ 
2010  -0.360 (0.030)‡ 
Month   
Jan  base 
Feb  -0.222 (0.042)‡ 
Mar  -0.318 (0.046)‡ 
Apr  -0.462 (0.043)‡ 
May  -0.514 (0.043)‡ 
June  -0.463 (0.042)‡ 
July  -0.621 (0.045)‡ 
Aug  -0.765 (0.046)‡ 
Sept  -0.829 (0.053)‡ 
Oct  -0.962 (0.055)‡ 
Nov  -1.138 (0.062)‡ 
Dec  -1.655 (0.056)‡ 
RX used   0.011 (0.022) 
CCI  -0.011 (0.021) 
Psych Comorbidities   
0  base 
1  0.050 (0.033) 
2  -0.012 (0.051) 
3  0.061 (0.118) 
4  0.195 (0.191) 
5  0.300 (0.210) 
Median Age  -0.006 (0.001) 
Female  -0.025 (0.022) 
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Table A4.2 continued. 
Estimate (SE) NULL MODEL FULL MODEL 
NB ESTIMATES   
Region   
North East  base 
Midwest  -0.283 (0.031)‡ 
South  -0.298 (0.030)‡ 
West  -0.095 (0.034)♦ 
Intercept 5.475 (0.025)‡ 6.227 (0.084)‡ 
Alpha 0.792 (0.014) 0.633 (0.009) 
LOGIT ESTIMATES   
Cost-Share (%) 0.007 (0.003)* 0.007 (0.003)* 
Plan Type   
Comprehensive base base 
EPO 0.314 (0.297) 0.313 (0.297) 
HMO -0.236 (0.156) -0.236 (0.156) 
POS-FFS -0.034 (0.155) -0.034 (0.155) 
POS-Cap 0.689 (0.578) 0.688 (0.577) 
PPO 0.032 (0.137) 0.032 (0.137) 
CDHP 0.108 (0.175) 0.108 (0.175) 
HDHP -0.441 (0.245) -0.441 (0.244) 
Cost-share* EPO -0.011 (0.007) -0.011 (0.007) 
Cost-share*HMO 0.005 (0.004) 0.005 (0.004) 
Cost-share*POS-FFS -0.005 (0.003) -0.005 (0.003) 
Cost-share*POS-Cap -0.036 (0.015)* -0.036 (0.015)* 
Cost-share*PPO -0.004 (0.003) -0.004 (0.003) 
Cost-share*CDHP -0.004 (0.004) -0.004 (0.004) 
Cost-share*HDHP 0.001 (0.004) 0.001 (0.004) 
Year   
2008 base base 
2009 -0.006 (0.040) -0.006 (0.040) 
2010 0.158 (0.043)‡ 0.157 (0.043)‡ 
Month   
Jan base base 
Feb 0.429 (0.061)‡ 0.428 (0.061)‡ 
Mar 0.494 (0.060)‡ 0.494 (0.059)‡ 
Apr 0.601 (0.058)‡ 0.600 (0.058)‡ 
May 0.619 (0.059)‡ 0.618 (0.059)‡ 
June 0.662 (0.058)‡ 0.661 (0.057)‡ 
July 0.706 (0.058)‡ 0.704 (0.058)‡ 
Aug 0.894 (0.063)‡ 0.893 (0.063)‡ 
Sept 0.994 (0.066)‡ 0.993 (0.066)‡ 
Oct 0.905 (0.075)‡ 0.903 (0.075)‡ 
Nov 1.120 (0.087)‡ 1.118 (0.087)‡ 
Dec 1.468 (0.094)‡ 1.465 (0.094)‡ 
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Table A4.2 continued. 
Estimate (SE) NULL MODEL FULL MODEL 
LOGIT ESTIMATES   
Psych Comorbidities   
0 base base 
1 -0.144 (0.048)♦ -0.144 (0.048)♦ 
2 -0.389 (0.078)‡ -0.389 (0.078)‡ 
3 -0.747 (0.147)‡ -0.746 (0.147)‡ 
4 -0.519 (0.360) -0.519 (0.360) 
5 -0.045 (0.766) -0.045 (0.766) 
Intercept 0.245 (0.142) 0.247 (0.142) 
Notes: ‡: p <.001 ♦: p <.01 *: p <.05   
SE: standard error  
EPO: exclusive provider organization  
HMO: health maintenance organization  
POS-FFS: point of service – fee-for-service  
POS-Cap: point of service capitated  
PPO: preferred provider organization  
CDHP: consumer-directed high-deductible  
HDHP: high-deductible health plan 
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Table A4.3. Comparison of null model to full model Logistic regression model estimates for probability 
of adherence, defined as MPRm ≥0.80. Estimates are presented as log odds. N= 16,691 encounters with at 
least one SRI dispensed. SEs are adjusted for 11,093 family clusters.  
Estimate (SE) NULL MODEL FULL MODEL 
Wald X
2 
0.82 173.68 
Pr > X
2 
0.3639 <0.001 
Pseudo R
2 
0.0000 0.0086 
Cost-Share (%) 0.0007 (0.0008) 0.0003 (0.0008) 
Plan Type   
Comprehensive  base 
EPO  -0.034 (0.174) 
HMO  -0.236 (0.109)* 
POS-FFS  -0.076  (0.110) 
POS-Cap  0.142 (0.264) 
PPO  -0.122 (0.099) 
CDHP  -0.131 (0.130) 
HDHP  0.050 (0.162) 
Any Psychotherapy  -0.323 (0.041)‡ 
Year   
2008   base 
2009  0.007 (0.043) 
2010  0.006 (0.047) 
Month   
Jan  base 
Feb  0.103 (0.071) 
Mar  -0.045 (0.069) 
Apr  -0.054 (0.067) 
May  -0.049 (0.069) 
June  -0.020 (0.067) 
July  0.019 (0.067) 
Aug  -0.004 (0.070) 
Sept  0.073 (0.071) 
Oct  0.058 (0.084) 
Nov  0.278 (0.095)♦ 
Dec  0.815 (0.118)‡ 
CCI  -0.020 (0.035) 
Psych Comorbidities   
0  base 
1  -0.081 (0.051) 
2  -0.018 (0.090) 
3  -0.052 (0.179) 
4  -0.673 (0.425) 
5  -0.821 (0.892) 
Median Age  0.001 (0.001) 
Female  0.026 (0.036) 
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Table A4.3 continued. 
Estimate (SE) NULL MODEL FULL MODEL 
Region   
North East  base 
Midwest  0.064 (0.052) 
South  0.010(0.049) 
West  0.110 (0.061) 
intercept 0.068 (0.031)* 0.175 (0.137) 
Notes: ‡: p <.001 ♦: p <.01 *: p <.05   
SE: standard error  
EPO: exclusive provider organization  
HMO: health maintenance organization  
POS-FFS: point of service – fee-for-service  
POS-Cap: point of service capitated  
PPO: preferred provider organization  
CDHP: consumer-directed high-deductible  
HDHP: high-deductible health plan 
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Table A4.4. Sensitivity analysis of average marginal effects estimates of SRI medication possession ratio-modified based on logistic regression 
estimates various MPRm thresholds. Estimates represent the change in probability of being adherent for each percentage point increase in cost-
share. N= 16,205 encounters with at least one SRI dispensed.  
Estimate (SE) MPRm ≥ .50 MPRm ≥ .60 MPRm ≥ .70 MPRm ≥ .80 MPRm ≥ .90 MPRm ≥ .95 
Cost-share -0.00012 
(0.0001) 
-0.00005 
(0.0001) 
0.00008 (0.0002) 0.00008 (0.0002) -0.00011 (0.0002) -0.00007 (0.0002) 
Plan type       
Comprehensive  base base base base base base 
EPO -0.005 (0.024) -0.008 (0.032) 0.008 (0.037) -0.008 (0.043) -0.013 (0.040) -0.036 (0.036) 
HMO -0.011 (0.015) -0.014 (0.021) -0.019 (0.025) -0.059 (0.027)* -0.041 (0.026) -0.043 (0.024) 
POS-FFS -0.014 (0.015) -0.005 (0.021) -0.010 (0.025) -0.019 (0.027) -0.000 (0.027) -0.012 (0.024) 
POS-Cap -0.005 (0.034) 0.079 (0.040)* 0.035 (0.052) 0.034 (0.063) -0.034 (0.067) -0.025 (0.063) 
PPO -0.015 (0.014) -0.008 (0.019) -0.024 (0.023) -0.030 (0.024) -0.015 (0.024) -0.023 (0.022) 
CDHP -0.018 (0.018) -0.013 (0.025) -0.035 (0.030) -0.032 (0.032) -0.044 (0.032) -0.035 (0.029) 
HDHP -0.030 (0.025) -0.014 (0.033) 0.019 (0.036) 0.012 (0.039) -0.068 (0.039) -0.076 (0.034) 
Any Psychotherapy -0.090 (0.007)‡ -0.095 (0.009)‡ -0.093 (0.010)‡ -0.080 (0.010)‡ -0.070 (0.009)‡ -0.051 (0.008)‡ 
Year       
2008 base base base base base base 
2009 -0.007 (0.007) -0.008 (0.009) 0.004 (0.010) 0.002 (0.011) 0.006 (0.010) 0.014 (0.009) 
2010 0.01328 (0.007) 0.009 (0.009) 0.007 (0.011) 0.002 (0.012) 0.014 (0.011) 0.025 (0.010)♦ 
Month       
Jan base base base base base base 
Feb 0.016 (0.011) 0.009  (0.014) 0.025 (0.016) 0.026 (0.017) 0.026 (0.017) 0.024 (0.015) 
Mar 0.001 (0.011) -0.003 (0.014) -0.000 (0.016) -0.011 (0.017) 0.002 (0.016) 0.011 (0.014) 
Apr 0.003 (0.011) -0.005 (0.014) 0.000 (0.016) -0.013 (0.017) -0.009 (0.016) 0.004 (0.014) 
May 0.005 (0.011) 0.016 (0.014) 0.010 (0.016) -0.012 (0.017) 0.007 (0.016) 0.015 (0.014) 
June 0.028 (0.010)♦ 0.019 (0.013) 0.015 (0.016) -0.005 (0.017) -0.011 (0.015) -0.001 (0.014) 
July 0.021 (0.010)* 0.007 (0.014) 0.015 (0.016) 0.005 (0.017) 0.035 (0.016)* 0.026 (0.014) 
Aug 0.010 (0.011) 0.006 (0.014) 0.011 (0.016) -0.001 (0.017) 0.019 (0.017) 0.018 (0.015) 
Sept 0.032 (0.011)♦ 0.027 (0.014) 0.024 (0.017) 0.018 (0.018) 0.028 (0.017) 0.036 (0.015)* 
Oct 0.049 (0.011)‡ 0.036 (0.016)* 0.022 (0.020) 0.014 (0.021) 0.028 (0.020) 0.019 (0.017) 
Nov 0.072 (0.011)‡ 0.084 (0.017)‡ 0.084 (0.021)‡ 0.068 (0.023)♦ 0.048 (0.022)* 0.051 (0.020)* 
DEC 0.108 (0.010)‡ 0.015 (0.016)‡ 0.170 (0.022)‡ 0.190 (0.025)‡ 0.156 (0.026)‡ 0.100 (0.024)‡ 
CCI -0.008 (0.004) -0.015 (0.006)* -0.012 (0.008) -0.005 (0.009) 0.009 (0.008)  0.011 (0.007) 
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Table A4.4 continued. 
Estimate (SE) MPRm ≥ .50 MPRm ≥ .60 MPRm ≥ .70 MPRm ≥ .80 MPRm ≥ .90 MPRm ≥ .95 
       
Psych. Comorbidities       
0 base base base base base base 
1 -0.023 (0.008)♦ -0.036 (0.011)♦ -0.028 (0.012)* -0.020 (0.013) -0.010 (0.012) -0.000 (0.011) 
2 -0.036 (0.014)* -0.041 (0.018)* -0.010 (0.021) -0.004 (0.022) 0.000 (0.021) -0.004  (0.018) 
3 0.008 (0.023) -0.037 (0.035) -0.032 (0.040) -0.013 (0.044) -0.028 (0.043) 0.028 (0.041) 
4 -0.234 (0.102)* -0.186 (0.104) -0.253 (0.101)* -0.163 (0.097) -0.074 (0.094) -0.016 (0.088) 
5 -0.220 (0.190) -0.126 (0.192) -0.168 (0.203) -0.196 (0.195) not est. not est. 
Median Age 0.001  (0.000)‡ 0.001 (0.000)♦ 0.001 (0.000) 0.000 (0.000) -0.000 (0.000) -0.000 (0.000) 
Female -0.016 (0.005)♦ -0.007 (0.007) 0.007 (0.008) 0.006 (0.009) 0.002 (0.008) 0.010 (0.007) 
Region       
Northeast base base base base base base 
Midwest 0.014 (0.007) 0.022 (0.010)* 0.022 (0.012) 0.016 (0.013) -0.004 (0.012) -0.013 (0.011) 
South 0.009 (0.007) 0.013 (0.010) 0.015 (0.011) 0.002 (0.012) -0.012 (0.011) -0.025 (0.010)* 
West 0.006 (0.009) 0.012 (0.012) 0.016 (0.014) 0.027 (0.015) 0.018 (0.014) 0.012 (0.013) 
Notes: ‡: p <.001 ♦: p <.01 *: p <.05   
SE: standard error  
EPO: exclusive provider organization  
HMO: health maintenance organization  
POS-FFS: point of service – fee-for-service  
POS-Cap: point of service capitated  
PPO: preferred provider organization  
CDHP: consumer-directed high-deductible  
HDHP: high-deductible health plan
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